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Purpose: The purpose of this analysis was to assess
the cost-effectiveness of apixaban 5 mg BID versus
high- and low-dose edoxaban (60 mg and 30 mg once
daily) as intended starting dose strategies for stroke
prevention in patients from a UK National Health
Service perspective.
Methods: A previously developed and validated
Markov model was adapted to evaluate the lifetime
clinical and economic impact of apixaban 5 mg BID
versus edoxaban (high and low dose) in patients with
nonvalvular atrial ﬁbrillation. A pairwise indirect
treatment comparison was conducted for clinical end
points, and price parity was assumed between apix-
aban and edoxaban. Costs in 2012 British pounds,
life-years, and quality-adjusted life-years (QALYs)
gained, discounted at 3.5% per annum, were
estimated.
Findings: Apixaban was predicted to increase life
expectancy and QALYs versus low- and high-dose
edoxaban. These gains were achieved at cost-savings
versus low-dose edoxaban, thus being dominant and
nominal increases in costs versus high-dose edoxaban.
The incremental cost-effectiveness ratio of apixaban
versus high-dose edoxaban was £6763 per QALY
gained.
Implications: Apixaban was deemed to be domi-
nant (less costly and more effective) versus low-dose
edoxaban and a cost-effective alternative to high-dose
edoxaban. (Clin Ther. 2015;37:2476–2488) & 2015
The Authors. Published by Elsevier HS Journals, Inc.
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Nonvalvular atrial ﬁbrillation (NVAF) is the most
common sustained cardiac arrhythmia and a major
cause of stroke and thromboembolism, associated
with increased mortality, increased morbidity,
and high medical costs.1,2 Anticoagulation treatment
is therefore recommended to mitigate the risk of
stroke.3
The 2012 European Society of Cardiology guide-
lines recommend the consideration of the non–vitamin
K oral anticoagulants (NOACs) dabigatran, rivarox-
aban, and apixaban, for the prevention of stroke in
patients3 with NVAF because they offer relative
efﬁcacy, tolerability, and convenience by addressing
certain limitations associated with traditional vitamin
K antagonists (VKAs).
The NOACs have been compared with VKAs in
large Phase III randomized trials. The Randomized
Evaluation of Long-term Anticoagulation Therapy4
trial revealed superiority for dabigatran 150 mg BID
and noninferiority for dabigatran 110 mg BID versus
dose-adjusted VKAs in reducing the primary efﬁcacy
end point of stroke and systemic embolism. In
addition, dabigatran 110 mg was superior to dose-
adjusted VKAs in reducing the risk of major hemor-
rhage, whereas dabigatran 150 mg4 was noninferior.
The Rivaroxaban Once Daily Oral Direct Factor XaVolume 37 Number 11
G.Y.H. Lip et al.Inhibition Compared with Vitamin K Antagonism for
Prevention of Stroke and Embolism Trial in Atrial
Fibrillation5 trial found rixaroxaban 20 mg once daily
to be noninferior to dose-adjusted VKAs in efﬁcacy and
tolerability. The Apixaban for Reduction in Stroke and
Other Thromboembolic Events in Atrial Fibrillation
(ARISTOTLE)6 trial found that apixaban 5 mg BID
was superior to dose-adjusted VKAs in reducing stroke
and systemic embolism, major bleeding, and all-cause
death. Finally, the Phase III Study of Apixaban in
Patients With Atrial Fibrillation (AVERROES)7 trial,
evaluating apixaban 5 mg BID versus aspirin, in VKA-
unsuitable patients, found apixaban’s superiority to
aspirin in reducing the risk of stroke and systemic
embolism without signiﬁcantly increasing the risk of
major hemorrhage.7 Lack of monitoring requirement
and strength of efﬁcacy-tolerability data as observed in
NOAC trials resulted in the European Society of
Cardiology guidelines recommendation of NOACs
instead of dose-adjusted VKA treatment.3
None of the NOACs has been evaluated against
each other in head-to-head trials. Indirect treatment
comparisons (ITCs) have indicated no signiﬁcant
differences between the NOACs in efﬁcacy8,9; how-
ever, they found a reduced risk of major bleeding
among patients treated with apixaban or dabigatran
110 mg compared with dabigatran 150 mg and
rivaroxaban.8–10 Apixaban is the only NOAC that
received a Class 1, Evidence A classiﬁcation from the
American Heart Association/American Stroke Associ-
ation because it appears to have the best combination
of efﬁcacy and tolerability at the tested doses.11
However, no clear recommendation for the use of
one NOAC over another is provided; rather, cost is
highlighted as an important consideration in the
choice of agent.3
Most evaluations comparing a NOAC against
dose-adjusted VKAs for stroke prevention in patients
with NVAF concluded that the NOACs offer superior
beneﬁts and were cost-effective compared with dose-
adjusted VKAs.12–15 In addition, studies that com-
pared cost-effectiveness among the NOACs suggest
that apixaban may be the most cost-effective NOAC
(compared with rivaroxaban and dabigatran 150 mg
and 110 mg) for stroke prevention among patients
with NVAF.13–15
A recently introduced NOAC, edoxaban, is another
oral factor Xa inhibitor that has been studied in
dosages of 30 mg once daily (low dose) and 60 mgNovember 2015once daily (high dose) versus dose-adjusted VKAs in a
double-blind randomized clinical trial called Effective
Anticoagulation With Factor Xa Next Generation
in Atrial Fibrillation (ENGAGE-AF)—Thrombolysis in
Myocardial Infarction 48 (TIMI-48)16 and has recently
received European marketing authorization.17 Low-
dose edoxaban was numerically worse whereas high-
dose edoxaban once daily was numerically better than
dose-adjusted VKAs in reducing stroke and systemic
embolism. Both doses resulted in signiﬁcantly less
bleeding.16 Comparatively, low-dose edoxaban had a
better bleeding proﬁle but worse stroke prevention than
high-dose edoxaban.16
A recently published ITC10 reported that a high-
dose edoxaban regimen was broadly comparable in
efﬁcacy to apixaban and dabigatran 110 mg, but
apixaban was associated with lower risks of major
or clinically relevant nonmajor gastrointestinal bleed-
ing. High-dose edoxaban was broadly comparable in
efﬁcacy and tolerability to dabigatran 110 mg BID but
had lower efﬁcacy compared with dabigatran 150 mg.
There were no differences in efﬁcacy end points
between high-dose edoxaban and rivaroxaban, but
the latter was associated with more bleeding. Low-
dose edoxaban was less efﬁcacious compared with
apixaban, dabigatran 150 mg, and rivaroxaban but
had fewer major bleedings and was generally more
tolerable than all the other alternatives.
The addition of edoxaban to the options of avail-
able NOACs may change the relative value of these
NOACs from a payer perspective. A holistic assess-
ment of clinical beneﬁts versus risks extrapolated over
lifetime is required to determine the relative value and
overall clinical beneﬁt of various NOACs. The aim of
this study was to reexamine the hypothesis that
apixaban may be the most cost-effective NOAC,
taking the emergence of edoxaban into account. We
therefore assessed the cost-effectiveness of apixaban
5 mg BID versus edoxaban (low dose and high dose)
as intended starting-dose strategies for stroke preven-
tion in patients with NVAF from the UK National
Health Service (NHS) payer perspective.METHODS
A previously developed and validated18,19 Markov
model12,13 was adapted to evaluate the lifetime
clinical and economic impact of apixaban versus
edoxaban (low and high dose) in patients with NVAF.2477
Table I. Demographic characteristics of the study
participants.12,13
Characteristic Finding
Starting age, y 70
Sex, %
Male 64.7
Female 35.3
CHADS2 distribution, %
0–1 34.0
2 35.8
3–6 30.2
Clinical TherapeuticsLong-term costs resulting from a lifetime model, as
opposed to one with a speciﬁed duration, tend to be
high. This Markov model explored how a hypothet-
ical cohort of patients with NVAF move between
discrete health states during a lifetime. During each
6-week cycle, the recurring ﬁxed interval that deter-
mines disease progression, patients transitioned
through or remained in the following mutually ex-
clusive states: NVAF, ischemic stroke (including non-
speciﬁed strokes), systemic embolism, intracranial
hemorrhage, other major bleeds, clinically relevant
nonmajor bleeds, myocardial infarction, treatment
discontinuations, and death. Possible transitions
among the end points based on the likelihood of
occurrence of events are presented in Figure 1, as
described in previous publications.12,13 Similarly to
assumptions used in earlier studies,12,13 patients dis-
continuing their ﬁrst-line treatment were assumed to
receive aspirin as a second-line treatment (Figure 1).
Model inputs on patient characteristics and rates
of clinical events per 100 patient-years for apixaban
and warfarin users were based on ARISTOTLE,6 as
obtained from a previously published cost-effectivenessApixaban
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2478analysis,12,13 and brieﬂy summarized in Tables I, II, and
III. Patients discontinuing their ﬁrst-line treatment were
treated with aspirin, and event rates due to the subse-
quent treatment were drawn from a cohort of patients in
the AVERROES trial with prior VKA exposure.7,12,13
Further details on the model design, inputs, and ITC esti-
mations of event rates of low- and high-dose edoxaban
versus apixaban are available in the Appendix.NVAF
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Table II. Clinical event rates per 100 patient-years.12,13
Event
Event Rate per 100
Patient-years, Mean
(number of events) HR Versus Apixaban (95% CI)*
Apixaban
Aspirin
(Subsequent
Treatment) Edoxaban (30 mg) Edoxaban (60 mg)
Ischemic stroke 0.981 (162) 3.45 (43) 1.480 (1.120–1.960) 1.040 (0.780–1.390)
Intracranial hemorrhage 0.330 (52) 0.32 (4) 0.740 (0.460–1.200) 1.110 (0.710–1.730)
Other major bleed 1.790 (274) 0.89 (11) 0.660 (0.530–0.830) 1.130 (0.910–1.390)
Clinically relevant nonmajor bleed 2.083 (318) 2.94 (36) 0.950 (0.800–1.130) 1.250 (1.060–1.480)
Other treatment discontinuation 13.177 (2047) NA 1.040 (0.960–1.130) 1.100 (1.010–1.190)
Myocardial infarction 0.530 (90) 1.11 (14) 1.370 (0.950–1.960) 1.070 (0.741–1.550)
Systemic embolism 0.090 (15) 0.40 (13) 1.390 (0.570–3.360) 0.740 (0.290–1.920)
Other cardiovascular
hospitalization
10.460 12.09 1.000 (0.900–1.100) 1.000 (0.900–1.100)
Other death rate† 3.082 (528) NA 1.000 (0.900–1.100) 1.000 (0.900–1.100)
HR ¼ hazard ratio; NA ¼ not applicable.
*Data are based on the Appendix except for other cardiovascular hospitalization and other death rate, which are based on
assumption.
†Based on all-cause mortality excluding deaths attributable to stroke, bleeding, myocardial infarction, and systemic
embolism.
G.Y.H. Lip et al.In summary, relative effects in the form of hazard
ratios (HRs) were computed using the Bucher method
on the following studies: ARISTOTLE6 (apixaban 5
mg BID versus warfarin; dose adjusted to maintain an
international normalized ratio [INR] of 2.0–3.0) and
ENGAGE-AF16 (low- and high-dose edoxaban versus
warfarin; dose adjusted to maintain an INR of 2.0–
3.0). That is, the HR between both doses of edoxaban
and apixaban were made via the warfarin common
arm in ENGAGE-AF16 and ARISTOTLE.6 The
(indirect) HR between apixaban and the edoxaban is
determined as follows:
logðHREVAÞ¼ logðHREVWÞ logðHRAVWÞ
With the SE determined as follows:
SE½ logðHREVAÞ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SE½ logðHREVWÞ2þSE½ logðHREVAÞ2
q
Mortality modelling was based on sex- and age-
speciﬁc UK life tables12,13,20 taking into consideration
increased mortality for patients with atrial ﬁbrillation
(AF)21 and that associated with various end pointsNovember 2015(ie, stroke, systemic embolism, or myocardial
infarction).22–24 Utility estimates were similarly ob-
tained from a UK EuroQol-5D–based catalogue,25 as
detailed in earlier publications (Table IV).12,13
The UK NHS perspective was adopted where only
direct medical costs, expressed in 2012 British pounds,
were considered (Tables V and VI). Detailed cost
calculations and assumptions have been previously pub-
lished.12 Acute event costs were revised to reﬂect updated
NHS reference costs.27 In addition, estimates of the health
care costs associated with strokes were revised based on
an updated population-based study, The Oxford Vascular
Study.28 In the absence of pricing information for
edoxaban, price parity to apixaban was assumed. Cost
and health outcomes were discounted at a rate of 3.5%
per annum29 during a lifetime.Analyses
The total number of clinical events observed among
a cohort of 1000 patients treated with apixaban
compared with high- and low-dose edoxaban was2479
Table III. Distributions and probabilities by treatment.12,13,16
Stroke Severity
No. (%) of Patients
Apixaban
Aspirin
(Subsequent Treatment)
Edoxaban
(30 mg)
Edoxaban
(60 mg)
Stroke severity distribution*
Mild (mRS score, 0–2) 57 (53) 35 (36) 135 (50) 102 (47)
Moderate (mRS score, 3–4) 23 (21) 37 (38) 78 (22) 50 (18)
Severe (mRS score, 5) 9 (8) 15 (15) 28 (8) 18 (6)
Fatal (mRS score, 6) 19 (18) 10 (11) 73 (20) 80 (29)
Hamorrhagic stroke among intracranial
hemorrhage
40 (77) 9 (55) 41 (69) 61 (75)
Hemorrhagic stroke severity distribution*
Mild (mRS score, 0–2) 7 (23) 1 (7) 135 (50) 102 (47)
Moderate (mRS score, 3–4) 10 (32) 3 (20) 78 (22) 50 (18)
Severe (mRS score, 5) 3 (10) 4 (27) 28 (8) 18 (6)
Fatal (mRS score, 6) 11 (35) 7 (46) 73 (20) 80 (29)
Gastrointestinal bleeds among other
major bleeds†
105 (38) 7 (39) 129 (61) 232 (65)
Patients experiencing dyspepsia 152 (1.67) 44 (1.58) 152 (1.67) 152 (1.67)
mRS ¼ modiﬁed Rankin scale.
*The number of nondisabling (mRS 0–2), disabling (mRS 3–6), and fatal (mRS 6) strokes was available for edoxaban; therefore,
the distribution of disabling strokes between mRS 3 to 4 and mRS 5 was calibrated assuming the same distribution as that
observed in the apixaban arm. The number of mild, moderate, severe and fatal strokes in patients treated with subsequent aspirin
was estimated based on pooled data from both the apixaban and aspirin arms in AVERROES due to small number of events.
†Based on all-cause mortality excluding deaths attributable to stroke, bleeding, myocardial infarction, and systemic embolism.
Clinical Therapeuticsassessed during a lifetime. Key clinical events included
were total number of strokes and systemic embolisms,
including ﬁrst and recurrent ischemic and hemorrha-
gic strokes, and total number of major bleeds. In
addition, total costs, life-years gained, and quality-
adjusted life-years (QALYs) gained were estimated for
each treatment during a lifetime. Relative economic
value was assessed through the use of incremental
cost-effectiveness ratios (ICERs), using the UK payer’s
commonly used willingness-to-pay threshold of
£20,000 to 30,000 per QALY gained.29
To explore the impact of various inputs, univariate
sensitivity analyses were performed, where event risks,
HRs, utility, and cost inputs were varied by their CIs.
The most inﬂuential parameters were depicted
through tornado diagrams.
Probabilistic sensitivity analysis was performed,
whereby key model inputs were varied by randomly
selecting values from assigned probability distributions2480during 2000 simulated model runs (called trials runs) to
produce a number of incremental QALYs and costs in
the form of a scatterplot.12,13 A cost-effectiveness
acceptability curve was then produced based on the
probability of generating the maximum net beneﬁt
across comparators. The parameters and ranges, as
well as distributions used in the univariate and proba-
bilistic sensitivity analysis, are detailed in the Appendix.
RESULTS
Base Case Analysis
Table VII gives the predicted number of clinical
events that correspond to each treatment for a cohort
of 1000 VKA-suitable patients with NVAG during a
lifetime. Apixaban, in comparison with low-dose edox-
aban and high-dose edoxaban, resulted in 18 and 6 fewer
strokes or systemic embolisms, respectively. Apixaban
caused 53 more major bleeds than low-dose edoxaban
but 9 fewer compared with high-dose edoxaban.Volume 37 Number 11
Table IV. Utility estimates for each health
state.24,26
Health state Utility, Mean (SE)
Health state
Nonvalvular atrial
ﬁbrillation
0.7270 (0.0095)
Ischemic or hemorrhagic stroke
Mild 0.6151 (0.0299)
Moderate 0.5646 (0.0299)
Severe 0.5142 (0.0299)
Myocardial infarction 0.6098 (0.0299)
Systemic embolism 0.6265 (0.0299)
Transient health state or anticoagulant use*
Other intracranial
hemorrhage (6 weeks)
0.1511 (0.0401)
Other major bleeds
(2 weeks)
0.1511 (0.0401)
Clinically relevant
nonmajor bleeds
(2 days)
0.0582 (0.0173)
Other cardiovascular
hospitalization (6 days)
0.1276 (0.0259)
Treatment with warfarin
(while receiving
treatment)
0.0130 (0.00–0.08)
Treatment with apixaban,
edoxaban, or aspirin
(while receiving treatment)
0.0020 (0.00-0.04)
*Utility decrements.
Table V. Drug acquisition costs.30
Drug Daily Cost, £
Apixaban (5 mg BID) 2.20
Warfarin (mean, 5 mg daily) 0.04
Aspirin (75 mg BID) 0.02
Edoxaban (30 mg once daily)* 2.20
Edoxaban (60 mg once daily)* 2.20
*Data are based not only on Electronic Drug Tariff
2013, Department of Health by the NHS Business
Services Authority, NHS Prescription Services30 but
also on assumption.
G.Y.H. Lip et al.The reduction in stroke and systemic embolism
events resulted in 0.073 gains in QALYs and in cost-
savings of £48 per patient over a lifetime, when
comparing apixaban with low- and high-dose edox-
aban. The same event reduction resulted in 0.037
gains in QALYs and in additional costs of £248 per
patient for apixaban compared with high-dose
edoxaban.
Positive gains in QALYs and cost-savings deemed
apixaban a dominant treatment alternative to low-
dose edoxaban. Apixaban was deemed to be cost-
effective versus high-dose edoxaban with an ICER of
£6703 per QALY gained, below the commonly
accepted threshold of £20,000 per QALY gained.29November 2015Sensitivity Analyses
The tornado diagrams (Figure 2A and B) present
the deterministic sensitivity analyses results, depicting
the parameters with the greatest impact on the ICER.
The ICERs of apixaban versus low-dose edoxaban
were below the commonly accepted threshold of
£20,000 per QALY in all variations studied and
varied between apixaban being dominant (ie, apix-
aban costing less while being at least as effective as
the comparator) and £9511 per QALY gained. For the
analysis of apixaban versus high-dose edoxaban, the
ICERs similarly varied from apixaban being dominant
in some scenarios to being dominated in one scenario.
Key sensitivity analysis scenarios in which apixaban
was not a cost-effective alternative versus high-dose
edoxaban were the following: (1) assuming a reduc-
tion in ischemic stroke risk for high-dose edoxaban
and (2) assuming high-dose edoxaban has a beneﬁt
compared with apixaban in reducing the risk of deaths
unrelated to stroke and major bleedings.
Probabilistic Sensitivity Analysis
Results of the probabilistic sensitivity analysis are
plotted as the difference in the total aggregate costs
between apixaban and edoxaban on the y-axis versus
difference in QALYs accrued through lifetime use of
these drugs on the x-axis (also known as cost-
effectiveness plane) (Figure 3). The cost-effectiveness
planes illustrate the cost and effect combinations of
different strategies, as obtained by accounting for the
uncertainty surrounding the base case inputs.
As depicted in Figure 3, in comparison to low-dose
and high-dose edoxaban, most simulations were2481
Table VI. Cost input from UK National Health Service payer perspective.27,28,30
Event
Acute Care Cost,
£ (95% CI)
Long-term Maintenance Cost
per Month, £ (95% CI)
Ischemic stroke
Mild 3639 (0–27,660) 190 (0–1144)
Moderate 18,986 (304–74,273) 371(0–2370)
Severe 25,931 (3667–69,504) 564 (0–4448)
Fatal 3273 (136–11,228)
Hemorrhagic stroke
Mild 10,597 (3351–21,939) 190 (0–1144)
Moderate 27,224 (10,922–50,840) 371 (0–2370)
Severe 46,050 (26,322–71,206) 564 (0–4448)
Fatal 1704 (12–7292)
Myocardial infarction 2368 (1721–2826) 9 (5–13)
Systemic embolism 4221 (0–27,910) 190 (0–1144)
Other intracranial hemorrhage 3231 (2415–3796)
Gastrointestinal bleeds 1625 (1274–1854)
Nonintracranial or nongastrointestinal-related bleed 3847 (2496–4560)
Clinically relevant nonmajor bleeding 1183 (864–1372)
Other cardiovascular hospitalization 1770 (1275–1999)
Clinical Therapeuticslocated in the northeast and southeast quadrants,
indicating that apixaban was more effective than
either of these treatment options. Compared with
low-dose edoxaban, apixaban was cost-saving and
more effective in 36% of simulations. Apixaban was
more effective, albeit at a slight incremental cost
accrued due to lower discontinuation rates, with an
ICER below £20,000 per QALY gained (ie, cost-
effective) in 87% of simulations (Figure 3A).
Compared with high-dose edoxaban, apixaban was
dominant (ie, cost-saving and more effective) in 39%
of simulations. Apixaban was more costly and more
effective, with an ICER below the £20,000 per QALY
gained threshold in 72% of simulations (Figure 3B).
The cost-effectiveness acceptability curve, including
apixaban and low- and high-dose edoxaban 60 mg
(Figure 4), highlights that apixaban has the highest
probability of being the most cost-effective treatment
at a willingness-to-pay threshold of £3000 per QALY
gained and above.
DISCUSSION
In this study, we found that apixaban provided cost-
savings and greater QALY gains (thus dominant)2482versus low-dose edoxaban and was a cost-effective
alternative to high-dose edoxaban for the prevention
of stroke and other thromboembolic events during a
lifetime. From the payer perspective, our analysis
reveals that apixaban has the potential not only to
be cost-effective compared with dabigatran and rivar-
oxaban but also to yield dominance or robust cost-
effectiveness against edoxaban.
The model used in this study followed the estab-
lished structure of a previously published cost-
effectiveness model12,13 but was expanded to include
indirect comparisons against both doses of edoxaban,
using the updated cost data from the most recent
published estimates for costs of stroke28 and current
NHS reference costs.27 This analysis is the ﬁrst to
compare the cost-effectiveness of a NOAC versus
edoxaban, with only one study previously assessing
the cost-effectiveness of edoxaban versus warfarin from
an Italian NHS perspective.31 Our analysis indicates
that apixaban-dominated low-dose edoxaban was cost-
effective compared with high-dose edoxaban at an
ICER of £6703 per QALY gained. We only found 2
clinical scenarios in which apixaban was not cost-
effective to high-dose edoxaban, namely, (1) assumingVolume 37 Number 11
Table VII. Base case results: total number of events, costs, life-years, and QALYs in cohort of 1000 patients
with nonvalvular atrial fibrillation.
Variable Apixaban Edoxaban (30 mg) Edoxaban (60 mg)
No. of events
Stroke or systemic embolism* 298 316 304
Major bleeding† 204 151 213
Myocardial infarction 84 92 87
Other cardiovascular hospitalization 1,186 1,156 1,184
Other treatment discontinuation 635 633 656
Health outcomes (per patient)
Life-years (undiscounted) 8.810 8.728 8.761
QALYs (discounted) 6.260 6.187 6.223
Costs (discounted per patient), £
Clinical event costs 7223 7334 7182
Anticoagulants and management 3547 3484 3333
Monitoring 109 109 116
Total 10,879 10,927 10,631
Incremental results (apixaban vs edoxaban)
QALYs 0.073 0.037
Costs, £ 48 248
Incremental cost-effectiveness ratio, £ Dominant 6703
QALYs ¼ quality-adjusted life-years.
*Stroke or systemic embolism: ﬁrst and recurrent ischemic and hemorrhagic stroke and systemic embolism.
†Major bleeding: ﬁrst and recurrent hemorrhagic stroke, other intracranial hemorrhage, and other major bleeds.
G.Y.H. Lip et al.an ischemic stroke risk reduction for high-dose edox-
aban compared with apixaban and (2) assuming high-
dose edoxaban has a beneﬁt in reducing the risk of
deaths unrelated to stroke and major bleedings com-
pared with apixaban. However, ITC data based on
ENGAGE-AF and ARISTOTLE does not support
either of these scenarios. This ﬁnding is consistent with
ﬁndings from other published ITCs that found no
signiﬁcant differences between high-dose edoxaban
and apixaban in reducing stroke or systemic embolism
or all-cause mortality.10 Such evidence weakens the
plausibility of high-dose edoxaban having a relative
effect of 0.80 and 0.90 compared with apixaban in the
reduction in the risk of ischemic stroke and death,
respectively (the ranges tested in scenario analysis).
Finally, clinical experts advise that there is no reason to
believe that the NOACs would differ in mortality
unrelated to stroke and bleeding events, further weak-
ening the plausibility that edoxaban has a positive
impact on other-cause mortality.November 2015Assuming price parity between apixaban and edox-
aban, apixaban provided cost-savings versus low-dose
edoxaban mainly because of a reduction in stroke events
and subsequently health care costs associated with stroke
during a lifetime. In our estimation, payers may prefer a
NOAC that yields cost-savings while also producing
greater beneﬁts in terms of QALYs gained. Compared
with high-dose edoxaban, reduction in health care costs
with apixaban due to the slight reduction in number of
strokes was offset by additional drug costs in apixaban-
treated patients due to longer life expectancy and fewer
major bleeds and subsequent discontinuations, both of
which lead to longer treatment times. Although data are
limited at this time, these aspects may prove to be
important from the patient perspective as ideal aspects
of anticoagulant care.
Similarly to the earlier published analyses,12,13
several caveats apply to our analysis. The use of
clinical trial data to inform event rates may not reﬂect
actual clinical practice rates in the UK population,2483
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Figure 2. One-way sensitivity analysis of apixaban versus edoxaban 30 mg (A) and apixaban versus edoxaban
60 mg (B). HR ¼ hazard ratio; ICER ¼ incremental cost-effectiveness ratio; ICH ¼ intracranial
hemorrhage; MI ¼ myocardial infarction; PY ¼ patient-years.
Clinical Therapeuticsalthough there is broad comparability between clinical
trials and real-world data for the NOACs.32 Baseline
characteristics used were similarly as observed in
ARISTOTLE for consistency with the event rates
used. However, an analysis of the UK General
Practice Research Database suggests the AF
population in the United Kingdom has a slightly
higher mean age compared with the mean observed
in ARISTOTLE (74 vs 70 years) and a higher proportion
of patients with low risk of score (ie, CHADS2 scores,
0–1).33 We therefore examined results when baseline2484characteristics were set to be equivalent to those
observed in a UK population in terms of age and
CHADS2 proﬁle. Compared with high-dose edoxaban,
this scenario resulted in a slight increase of the ICER to
£7044 per QALY gained, whereas compared with low-
dose edoxaban, apixaban remained dominant. This
ﬁnding suggests that our base case conclusions remain
unaltered, regardless of the source used to inform baseline
characteristics.
Furthermore, there is currently no available retail
price listed for edoxaban; therefore, our base caseVolume 37 Number 11
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Figure 3. Probabilistic sensitivity analyses for apixaban versus edoxaban 30 mg (A) and apixaban versus
edoxaban 60 mg (B). The scatterplots are a graphical illustration of cost-effectiveness.29
Simulations appearing in the northeast quadrant denote the intervention of interest is more
costly but generates more QALYs. Simulations appearing in the southeast quadrant denote the
intervention is cost-saving and more effective. From a payer’s perspective, new treatments should
provide more value in terms of QALYs for a patient, while not exceeding the payer’s willingness-to-
pay threshold. QALY ¼ quality-adjusted life-year.
G.Y.H. Lip et al.analysis assumes price parity to apixaban and dabiga-
tran. To address this limitation, the daily price of both
low- and high-dose edoxaban was varied by 20% as
part of the univariate sensitivity analysis, which
resulted in apixaban being cost-effective versus both
doses of edoxaban at willingness-to-pay thresholds
below £30,000 per QALY gained.
In the absence of head-to-head trials, an ITC was
used to obtain the treatment effects between apixaban
and both edoxaban doses. The ITC did not control forNovember 2015differences in baseline patient characteristics, such as
stroke risk measured by CHADS2 or quality of INR
control. Although the median center–based time in
therapeutic range was similar between the 2 trials
(66% in ARISTOTLE6 and 68% in ENGAGE-AF16),
the mean CHADS2 score was higher in ENGAGE-AF
(2.16 vs. 2.816, respectively). The higher CHADS2 score
is of particular importance because of its contribution to
stroke and major bleeding rates, which could explain the
differences observed in the VKA arm between2485
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Clinical TherapeuticsARISTOTLE6 and ENGAGE-AF.16 For example, the
event rate per 100 patient-years observed among VKA-
treated patients for stroke was 1.51 in ARISTOTLE and
1.69 in ENGAGE-AF. The major bleeding rate per 100
patient-years was 3.09 and 3.43 in ARISTOTLE16 and
ENGAGE-AF.6 A numerically improved HR for stroke
was observed among patients with higher CHADS2
scores for both edoxaban and apixaban compared
with VKA.6,16 It is therefore possible that the higher
CHADS2 score may have yielded a larger effect size for
edoxaban in ENGAGE-AF in stroke outcomes. The
converse may be possible for major bleeding outcomes
because the effect size for both apixaban and edoxaban
was numerically worsened among patients with higher
CHADS2 scores. However, the differences in treatment
effects observed for stroke and major bleeding between
the CHADS2 subgroups were not signiﬁcant in either of
the trials. We subsequently found the treatment effects
used in our analysis to reﬂect the best available evidence
in absence of head-to-head trials.
Results from the univariate sensitivity and probabil-
istic analysis revealed that apixaban still remained a cost-
effective alternative to both doses of edoxaban. There-
fore, the use of ITC data reﬂects a conservative scenario
and the best available evidence to inform this analysis.
From the payer perspective, it is of interest that
apixaban has the potential to be not only cost-effective2486compared with dabigatran and rivaroxaban but also
dominant or cost-effectiveness against edoxaban. This
ﬁnding can be attributed to the superiority of apixaban
versus warfarin in efﬁcacy and tolerability outcomes,6
whereas both doses of edoxaban have superiority to
warfarin in tolerability outcomes and noninferiority in
efﬁcacy outcomes.16 In this indirect analysis, apixaban
subsequently revealed a unique efﬁcacy and tolerability
balance versus edoxaban when compared based on
dosing regimens studied in NVAF trials.
CONCLUSION
Apixaban 5 mg BID provided cost-savings and greater
QALY gains (thus dominant) versus low-dose edox-
aban and was a cost-effective alternative to high-dose
edoxaban for the prevention of stroke and other
thromboembolic events during a lifetime from the
UK NHS perspective. Our study adds to the evidence
base with regard to the cost-effectiveness of apixaban
versus edoxaban, which would potentially be the
fourth NOAC drug to become available for the treat-
ment of patients with NVAF.
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G.Y.H. Lip et al.SUPPLEMENTARY APPENDIX TO “COST–
EFFECTIVENESS OF APIXABAN COMPARED
WITH EDOXABAN FOR STROKE PREVENTION
IN NON-VALVULAR ATRIAL FIBRILLATION”
Technical Model Documentation
OBJECTIVE
The objective of this appendix is to provide additional
technical documentation to the manuscript entitled
“Cost–effectiveness of Apixaban Compared with
Edoxaban for Stroke Prevention in Non-valvular
Atrial Fibrillation” to enable full technical transpar-
ency. In the sections below we provide further gran-
ularity and details on the model more speciﬁcally on
structure, inputs and detailed results to accompany the
manuscript. This appendix largely follows that pub-
lished in Doran et al (2014).1
MODEL STRUCTURE
NVAF STATE
All patients start with the non-valvular atrial ﬁbrilla-
tion (NVAF) state, deﬁned as patients with AF on
anticoagulation who have not yet experienced any event
within the model. Patients with NVAF may remain in the
same health state staying on anticoagulation assigned at
baseline if no events occur. The model simulates the
following clinical outcomes depending on treatment:NIschaemic/unspeciﬁed stroke (non-hemorrhagic)
○ Non-fatal
▪ Mild
▪ Moderate
▪ Severe
○ Fatalovem Non-fatal mild/moderate/severe and fatal recurrent
ischemic/unspeciﬁed stroke Intracranial hemorrhages (ICH)
○ Non-fatal
▪ Hemorrhagic stroke
 Mild
 Moderate
 Severe
▪ Other ICH
○ Fatal ICH
▪ Hemorrhagic stroke
▪ Other ICHber 2015○ Recurrent hemorrhagic strokes are considered
separately. Other Major bleeds
○ Non-fatal
▪ Gastrointestinal (GI)
▪ Other non-ICH and non-GI
○ Fatal
▪ Gastrointestinal (GI) bleeds
▪ Other non-ICH and non-GI Clinically relevant non-major (CRNM) bleeds
 Myocardial infarction (MI)
○ Non-fatal
○ Fatal Systemic embolism (SE)
○ Non-fatal
○ Fatal Other treatment discontinuations (discontinuations
unrelated to stroke (all types), SE, MI and bleeding) Other cardiovascular hospitalizations (CV hospital-
izations unrelated to stroke (all types) and MI) Other deaths (deaths unrelated to stroke (all types)
and bleeding)
Detailed descriptions and assumptions around each
clinical outcome (i.e., each event branch in Figure A1)
are described below.Stroke
Stroke events are segregated by ischemic and
hemorrhagic due to their different natures. Hemor-
rhagic strokes are considered as part of bleeding types.
The risk of ischemic stroke is dependent on current
anticoagulant and is adjusted each cycle to reﬂect
increased risks over time. Baseline ischemic stroke
risks for the cohort are determined by CHADS2
distribution among the cohort (i.e., weighted average
risk of distribution of CHADS2 and ischemic stroke
risk for each CHADS2 level). The model permits
analysis of the impact of CHADS2 on outcome
through changes in baseline characteristics of the
population (e.g., distribution of CHADS2 scores).
However, the model does not model change in
CHADS2 and its associated ischemic stroke risk
during the model time horizon (e.g., when patients
become older than 75 years old or experience a
stroke). The model, however, increases the risk of
ischemic stroke on per decade basis as described in the
manuscript.2488.e1
NVAF subsequent
ASA
NVAF subsequent
ASA
NVAF subsequent ASA
Death
Death
Death
Death
Death
Death
Death
NVAF
NVAF
NVAF
NVAF
NVAF
Myocardial
infarction
Mild HS
Moderate HS
Severe HS
Mild IS
Moderate IS
Severe IS
Systemic
embolism
Other AC Discontinuation
Other Deaths
Myocardial infarction
Fatal
Fatal
Fatal
Fatal
Fatal
Fatal
Non-fatal
Non-fatal
Non-fatal
Non-fatal
Non-fatal
Non-fatal
CRNM Bleed
Major Bleed
Stay on current AC
Discontinue AC
Discontinue ACOther ICH
ICH
Tmt Interruption (6wks)
Bleeding
Haemorrhagic stroke
Mild
Moderete
Severe
Mild
Moderete
Severe
Ischaemic Stroke
Systemic Embolism
No Change
Figure A1. Decision sub-tree for NVAF.
Clinical TherapeuticsOn the occurrence of an ischemic stroke, a distri-
bution of the modiﬁed Rankin scale (mRS) is applied
to determined fatal strokes (i.e., mRS 6) and three
severity levels of non-fatal strokes: mild (mRS 0-2),
moderate (mRS 3-4) and severe (mRS 5). All fatal
strokes are transferred to death state in the next cycle.
Patients who survived an ischemic stroke transition to
the three ischemic stroke health states: (i.e., mild,
moderate, severe) according to the severity distribu-
tion. Patients in each of the three ischemic stroke
health states are at risk of recurrent ischemic stroke
independently of prior treatment. Those determined to
have a recurrent ischemic stroke transition to recur-
rent stroke states (i.e., mild, moderate, severe) accord-
ing to the severity distribution while the remaining
patients stay on the same ischemic stroke health states.
The severity distribution of recurrent ischemic stroke
is conditioned on the severity of the prior stroke.2488.e2Recurrent ischaemic stroke states are treated as tunnel
states where an acute care cost is applied per episode
then the patients will transition to the most severe of
the ﬁrst or recurrent stroke health states. Only one
recurrent ischemic stroke is allowed for each patient.
All non-fatal ischemic stroke health states are mod-
elled as semi-absorbing states (Figure A2). This means
that once patients experience a non-fatal ischemic
stroke (including the recurrences); they can only
transition to death state, indicating that subsequent
events are not modeled.
Costs and health outcomes as well as hazard ratios
(HRs) of death vary by ischemic stroke severity. A
utility is assigned to patients with ischemic stroke
based on their severity. Post- ischemic stroke resource
use and costs are separated into acute and long-term
maintenance phases. Acute phase comprises the time
spent in hospitalization and rehabilitation facility.Volume 37 Number 11
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Figure A2. Decision sub-trees for stroke (ischemic and hemorrhagic).
G.Y.H. Lip et al.Upon the occurrence of an ischemic stroke event
patients may stay on the initially assigned anticoagulant
or switch to warfarin. Warfarin was selected as a switch
treatment as it is current standard of care (SoC) across the
world and physicians are more likely to prescribe warfarin
if a decision is made to switch patients after occurrence ofNovember 2015stroke. while, this has no impact in terms of effectiveness,
it reduces anticoagulation costs upon switch to warfarin.
Intracranial Hemorrhage (ICH)
Event rates for ICHs are differed across treat-
ments and are adjusted each cycle to reﬂect an2488.e3
Death
Death
Systemic
embolism
Figure A3. Decision sub-tree for systemic embolism.
*When an event is modeled as a transient state, the model
processes the event in such a way that: 1) Event cost is
applied based on a per-episode basis, i.e., a one-time ﬁxed
cost; 2) Utility decrement is applied for a deﬁned duration; 3)
Patients cycle back to their previous health state after the
event is processed, i.e., the model assumes no impact on
subsequent event risks and the AC treatment that follows.
Clinical Therapeuticsincrease in risk over time (e.g., due to aging). As
described earlier, the model allows an option of
having bleeding risks (i.e., risks of ICH, other major
bleeds, and CRNM bleeds) adjusted based on
quality of INR control represented as distribution
of cTTR. ICHs are further categorized into haemor-
rhagic strokes and other ICHs (i.e., subdural hem-
orrhage). Similarly to the risk of recurrent ischemic
strokes in patients who have already experienced
such an event, patients experiencing hemorrhagic
stroke are at risk of the recurrent hemorrhagic
strokes. Recurrent hemorrhagic stroke health states
are modeled as tunnel states where the acute care
costs are accrued and the patients’ then transition to
the most severe of ﬁrst or recurrent hemorrhagic
stroke health states. Hemorrhagic stroke states are
modelled as semi-absorbing health states (Figure A2);
therefore no subsequent events are modeled after
the occurrence of a hemorrhagic stroke apart from
recurrent hemorrhagic stroke events. Similar to
ischemic strokes, the risk of hemorrhagic stroke
increases over decade as described in the manu-
script. Similarly to ischemic strokes, severity levels
according to mRS are assigned to non-fatal cases
with costs, health outcomes and HRs of death varying
according to severity. Upon the occurrence of a
hemorrhagic stroke it is assumed that all patients
discontinue anticoagulant treatment completely.
Utilities are assigned based on severity level and
acute care costs and long-term maintenance
costs are accumulated similarly to patients with
stroke.
Upon the occurrence of the other ICH, the non-
fatal cases may discontinue anticoagulant treatment
temporarily for a period of a cycle (six weeks) as
advised by experts or discontinue anticoagulant treat-
ment completely according to observations of patients
restarting anticoagulation after warfarin-associated
ICH. Patients having their initially assigned antico-
agulant treatment interrupted are modelled as2488.e4transient state.* Patients who completely discontinue
their current anticoagulant are transferred to the
NVAF with subsequent ASA state and start on a
second line treatment which is assumed to be aspirin
in the base case. Apart from the acute mortality
associated with other ICHs, the model assumes no
additional impact on mortality. Utility decrement is
applied upon the occurrence of the other ICH for the
duration of six weeks.Other Major Bleeds
Similar to the ICHs, event rates for other major bleeds
are differed across treatments and are adjusted each cycle
to reﬂect an increase in risk over time and can be
adjusted by the distribution of cTTR. Other major bleeds
are classiﬁed into GI bleeds and non-GI/non-ICH related
bleeds. Patients who survive GI or non-GI/non-ICH
related bleeds may stay on their initially assigned anti-
coagulant or discontinue the current anticoagulant treat-
ment. Those staying on the initial anticoagulant are
modeled as transient state.* Those discontinuing the
treatment are transitioned to the NVAF with subsequent
ASA health state and get second line treatment started
(i.e., aspirin as base case). Upon the occurrence of other
major bleed, utility decrement is applied for two weeks as
used in Freeman et al. (2011)2 and no impact on long
term mortality is assumed. No differentiation in utilities
is made between the two types of major bleeds. Resource
use associated with other major bleeds includes acute
care costs which are applied on a per episode basis.
Other major bleeds are segregated by GI bleeds and
other non-ICH non-GI major bleeds and costed
accordingly.Volume 37 Number 11
G.Y.H. Lip et al.CRNM Bleeds
Similar as the other types of bleeding, CRNM
bleeds event rates are adjusted each cycle to reﬂect
an increase in risk over time and can be adjusted by
quality of INR control (i.e., by distribution of cTTR).
All patients experiencing CRNM bleeds are assumed
staying on their initially assigned anticoagulant and
are modeled as a transient state†. By deﬁnition of the
CRNM bleeds, no acute mortality and impact on long
term mortality are assumed. Utility decrement is
applied for a user-deﬁned duration (i.e., two days as
base case) and acute care costs are accrued upon the
occurrence of the event.
Myocardial Infarction (MI)
Event rates for MI are differed across treatments
and are adjusted each cycle to reﬂect an increase in
risk over time (e.g., due to aging). Patients who
experience an MI are assumed to discontinue treat-
ment as advised by experts. MI is a semi-absorbing
state therefore patients are not at risk for additional
events. Patients are expected to get standard anti-
coagulant hence such costs are not considered incre-
mental in nature. A utility associated with MI is
applied to patients in the health state. Post-MI
resource use consists of acute care. Maintenance costs
are accrued over a patient’s lifetime. Patients can
experience a fatal or non-fatal MI based on gender
speciﬁc case fatality rates. The long term impact of MI
on mortality is taken into account through applying
increased HRs of death.
Systemic Embolism (SE)
Patients who experience an SE may stay on the
initially assigned anticoagulant or switch to warfarin.
Warfarin was selected as a switch treatment as it is the
current SoC across the world and physicians are more
likely to prescribe warfarin if a decision is made to
switch patients after occurrence of SE. This has no
impact in terms of effectiveness but impacts anti-
coagulation costs. SE is a semi-absorbing state there-
fore patients are not at risk for additional events. A†When an event is modeled as a transient state, the model
processes the event in such a way that: 1) Event cost is
applied based on a per-episode basis, i.e., a one-time ﬁxed
cost; 2) Utility decrement is applied for a deﬁned duration; 3)
Patients cycle back to their previous health state after the
event is processed, i.e., the model assumes no impact on
subsequent event risks and the AC treatment that follows.
November 2015utility associated with SE is applied to patients in the
health state. Post-SE resource use consists of acute
care and maintenance costs are accrued over a
patient’s lifetime. Patients can experience a fatal or
non-fatal SE and the long term impact of SE on
mortality is taken into account through applying
increased HRs of death.
Other Deaths
Other deaths represent deaths from causes unre-
lated to strokes (all types), MI, SE and bleedings.
Patients identiﬁed experiencing deaths are transferred
to death state.
Other Treatment Discontinuation
Treatment discontinuations that are unrelated to
stroke (all types), MI, SE, and bleeding are explicitly
modelled. If patients discontinue treatment, they are
transferred to the NVAF with subsequent ASA state.
The patients are assumed to switch to second line
aspirin in the base case.
CV Hospitalization
CV hospitalisation is modeled in the background
and not as a health state. CV hospitalizations are
associated with an acute cost and a decrement in
utility. Since stroke (all types) and MI hospitalisations
are explicitly modeled, CV hospitalization rates ex-
clude hospitalizations due to strokes (all types) and
MIs to avoid double counting.
Stroke Health State (Figure 2)
As described earlier, non-fatal ischemic strokes and
non-fatal hemorrhagic health states are modeled as
semi-absorbing states, i.e. no risk associated with
subsequent events other than death. This means that
once patients experience a non-fatal stroke or hemor-
rhagic stroke patients can only transition to death
either through the tunnel state of one recurrent stroke
or through the semi-absorbing stroke health state
when their life expectancy have been reached. Thus
after the ﬁrst stroke event no subsequent events are
modelled apart from recurrence. Only one recurrence
is modeled.
SE and MI Health State (Figure A3 and Figure A4)
As described earlier, non-fatal SEs and MIs are
modeled as semi-absorbing states. This means that
once patients experience a non-fatal SE or MI,2488.e5
Death
Death
Myocardial
infarction
Figure A4. Decision sub-tree for myocardial infarction.
Clinical Therapeuticspatients can only transition to death when their
life expectancy have been reached, indicating
that subsequent events after SE or MI are not
modelled.NVA
NVAF subsequent
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Figure A5. Decision sub-tree for NVAF subsequent ASA
2488.e6NVAF with Subsequent ASA Health State
(Figure A5)
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G.Y.H. Lip et al.discontinue due to ICH or other major bleed. Patients,
who discontinue transition to NVAF with subsequent
ASA health state, are assumed to start a second line
aspirin treatment in the base case. However, the model
also allows for warfarin and no treatment (i.e., com-
pletely discontinue) as second line treatment options.
Note that warfarin is allowed as a second line treat-
ment only for the VKA suitable patients if the com-
parator analysed is not warfarin. For patients who
receive aspirin as their initial AC treatment, the model
assumes no treatment discontinuation if the second-line
treatment choice is aspirin. Upon a switch to second-
line use of aspirin, this model assumes no subsequent
treatment discontinuations and a constant risk of
bleeding, stroke, SE, and MI independent of duration
of second line treatment use, and prior anticoagulant
treatment or patient characteristics.Anticoagulant Treatment Choice Post an Event
Upon the occurrence of stroke or SE, all patients’
initially assigned aspirin were assumed to discontinue their
current treatment and switch to warfarin. All patients on
apixaban or warfarin were assumed to continue on the
original treatments, according to the expert opinions.
After an ICH, 56% of the patients switched treat-
ment (i.e., to aspirin in the base case). The remaining
44% had treatment interruption for six weeks.3 While
for an occurrence of other major bleeds, the same
assumption as in the Sorensen et al. (2009)4 was
employed in which 25% of the patients had treatment
switch (i.e., to aspirin in the base case).Clinical Event Rates
The clinical event rates in the model were obtained
from the apixaban clinical trials (i.e., AVERROES5
and ARISTOTLE6) as detailed in the manuscript and
previous publications.1,7 The rates per 100 patient
years were converted into risks per cycle (i.e., 6 weeks
– 42 days) using the following formula:NRate per day ¼ Rate per 100 patient years/365.25/100
 Risk per cycle ¼ 1 e(0.0038%*42)
For example, the rate per 100 patient years of MI
for patients on apixaban in the VKA suitable pop-
ulation and in the NVAF state is 0.53. The transition
probability from NVAF to MI per cycle is calculated
as follows:ovember 2015 Rate per day (MI) ¼ 0.53/365.25/100 ¼ 0.0145%
 Risk per cycle (MI) ¼ 1e(Rate per day *42) ¼
0.061%
Clinical event rates for edoxaban were derived
using the Indirect Treatment Comparison (ITC)
approach consistently with a previously published
study.7 In particular, indirect comparisons between
apixaban and edoxaban via warfarin as the com-
mon comparator were made using the Bucher
method8 and the reported hazard ratios (HRs). The
(indirect) HR between apixaban and the edoxaban is
given by:
logðHRAVBÞ¼ logðHRAVCÞ logðHRBVCÞ
With standard error given by:
SE½ logððHRAVBÞ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SE½ logððHRAVCÞ2þSE½ logððHRBVCÞ2
q
The obtained HRs for edoxaban are detailed in the
manuscript. For application in the model the event
rate for edoxaban was calculated using the following
formula: Rate per day (edoxaban) ¼ Rate per day (apix-
aban)* HR (edoxaban)
The transition risks from the NVAF health state
estimated in the ﬁrst cycle for a male population are
displayed in Table A1. Transition risks are only
displayed for the ﬁrst cycle, thus subsequent
transitions from each health state are not displayed,
but can be calculated in the same manner.Utilities
Patients were assigned utilities according to their
health states. Utility inputs were obtained from UK-
based utility catalogue.9 A baseline utility was applied
to all patients, based on a utility score speciﬁc for
patients with AF. Utilities were updated upon the
occurrence of stroke or haemorrhagic strokes with
different utility scores for different severity level (i.e.,
mild, moderate, severe).Utility for stroke health states
was calculated by subtracting the disutility associated
with acute cerebrovascular disorders as well as the
disutility associated with chronic co-morbidities from
the baseline AF utility. The utility did not vary by
severity, therefore to proxy for mild, moderate and
severe strokes weights of 0.5, 1, and 1.5 were applied
to the disutility respectively. Similarly utilities for MI2488.e7
Table A1. Transition Matrix from NVAF state for apixaban.
Apixaban Edoxaban 30mg Edoxaban 60mg
NVAF (100%-0.354%)*(100%-0.113%-
0.038%-0.206%-0.239%-0.010%-
0.061%-1.504%) ¼ 97.48%
(100%-0.354%)*(100%-
0.167%-0.028%-
0.136%-0.227%-0.014%-
0.084%-1.564%)¼
97.78%
(100%-0.354%)*(100%-
0.117%-0.042%-
0.232%-0.299%-
0.008%-0.065%-
1.653%)¼ 97.24%
Ischemic stroke (IS)† 0.113% 0.167% 0.117%
Mild IS ¼ 0.113%*53% ¼ 0.060% ¼ 0.167%*50% ¼ 0.084% ¼ 0.117%*47% ¼ 0.055%
Moderate IS ¼ 0.113%*21% ¼ 0.024% ¼ 0.167%*22% ¼ 0.037% ¼ 0.117%*18% ¼ 0.021%
Severe IS ¼ 0.113%*8% ¼ 0.009% ¼ 0.167%*8% ¼ 0.013% ¼ 0.117%*6% ¼ 0.007%
Fatal IS ¼ 0.113%*18% ¼ 0.020% ¼ 0.167%*20% ¼ 0.033% ¼ 0.117%*29% ¼ 0.034%
Intracranial
hemorrhage
(ICH)†
0.038% 0.028% 0.042%
Hemorrhagic stroke ¼ 0.038%*77% ¼ 0.029% ¼ 0.028%*69% ¼ 0.019% ¼ 0.042%*75% ¼ 0.032%
Mild HS ¼ 0.029%*23% ¼ 0.007% ¼ 0.019%*50% ¼ 0.010% ¼ 0.032%%*47%
¼ 0.000%
Moderate HS ¼ 0.029%*32% ¼ 0.009% ¼ 0.019%*22% ¼ 0.004% ¼ 0.032%*18% ¼ 0.006%
Severe HS ¼ 0.029%*10% ¼ 0.003% ¼ 0.019%*8% ¼ 0.002% ¼ 0.032%*6% ¼ 0.002%
Fatal HS ¼ 0.029%*35% ¼ 0.010% ¼ 0.019%*20% ¼ 0.004% ¼ 0.032%*29% ¼ 0.009%
Other intracranial
hemorrhage
¼ 0.038%*23% ¼ 0.009% ¼ 0.028%*31% ¼ 0.009% ¼ 0.042%*25% ¼ 0.011%
Non-fatal other
ICH
¼ 0.009%*87% ¼ 0.008% ¼ 0.009%*87% ¼ 0.008% ¼ 0.009%*87% ¼ 0.008%
Fatal other ICH ¼ 0.009%*13% ¼ 0.001% ¼ 0.009%*13% ¼ 0.001% ¼ 0.009%*13% ¼ 0.001%
Other major bleeds† 0.206% 0.136% 0.232%
Non-fatal other
major bleeds
¼ 0.206%*98% ¼ 0.202% ¼ 0.136%*98%¼0.013% ¼ 0.232%*98% ¼0.023%
Gastrointestinal
bleeds
¼ 0.206%*38% ¼ 0.078% ¼ 0.136%*61%¼0.083% ¼ 0.232%*65% ¼0.015%
Other non-
gastrointestinal
and non-ICH
major bleeds
¼ 0.206%*62% ¼ 0.127% ¼ 0.136%*39%¼0.053% ¼ 0.232%*35% ¼ 0.081%
Fatal other major
bleeds
¼ 0.206%*2% ¼ 0.004% ¼ 0.136%*2%¼0.003% ¼ 0.232%*2% ¼0.005%
Clinically relevant
non-major
bleeds†
0.239% 0.227% 0.299%
Systemic embolism 0.010% 0.014% 0.008%
Fatal systemic
embolism
¼ 0.010%*9% ¼ 0.001% ¼ 0.014%*9%¼0.001% ¼ 0.008%*9%¼0.001%
Non-fatal systemic
embolism
¼ 0.010%*91% ¼ 0.009% ¼ 0.014%*91%¼0.013% ¼ 0.008%*91%¼0.007%
(continued)
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Table A1. (continued).
Apixaban Edoxaban 30mg Edoxaban 60mg
Myocardial
infarction†
0.061% 0.084% 0.065%
Fatal Myocardial
infarction
¼ 0.061%*11% ¼ 0.007% ¼ 0.084%*11%- ¼
0.009%
¼ 0.065%*11% ¼ 0.007%
Non-fatal Myocardial
infarction
¼ 0.061%*89% ¼ 0.054% ¼ 0.084%*89% ¼ 0.075% ¼ 0.065%*89% ¼ 0.058%
NVAF subsequent
ASA
1.504% 1.564% 1.653%
Death‡ 0.354% 0.354% 0.354%
Note: Risks of IS, ICH, other major bleeds, CRNM bleeds, systemic embolism, myocardial infarction are applied to the
cohort remaining alive thus the risk of transition to each event is adjusted, however the unadjusted transition risks have been
presented to demonstrate how the clinical data has been translated.
†Risks of these events are adjusted each cycle by a factor.
‡Applied for the duration of ARISTOTLE i.e. 1.9 years. UK mortality rates with adjustment factors used thereafter.
G.Y.H. Lip et al.and SE were calculated by subtracting the disutility
associated with acute myocardial infarction and arte-
rial embolism from the utility of patients with AF.
Utility decrements were applied to patients upon the
occurrence of other ICHs, other major bleeds, CRNM
bleeds, and CV hospitalizations (unrelated to stroke
and MI) for certain duration speciﬁc for each event.
Utility decrements associated with use of warfarin and
aspirin were obtained from a study by Gage et al.
(1996).10 Utility decrements were applied additively.
Calculations performed to obtain the utility estimates
for health states are displayed in Table A2.Resource Use and Unit Costs
Costs are reﬂected in 2011-2012 prices. Where
publications were used all costs were inﬂated. The
model accrues costs for the following resource use
categories:NTreatment costs (i.e., costs of ACs)
 Monitoring costs (for patients treated with
warfarin) Management costs (i.e., costs related to dyspepsia,
renal monitoring required) Acute care costs associated with clinical events
(stroke, hemorrhagic stroke, other ICH, GI bleed,
non ICH and non ICH related major bleed, CRNM
bleed, and MI)ovember 2015 Costs of fatal ischemic and hemorrhagic strokes
 Long-term care costs for stroke, hemorrhagic
stroke, and MI Costs associated with other CV hospitalization
Treatment costs were obtained from the NHS drug
tariffs and the Monthly Index of Medical Specialties
(MIMS),11,12 and in the case of Edoxaban, price
parity with Apixaban was assumed. Table A3-A6
In the model, AC use is detailed by the size of the
tablets, the cost per tablet, and the daily dose. Using these
inputs, the number of tablets required per day and thus
the average cost per day were calculated (Table III). Daily
dose requirements were inputted according to guidelines.
Note that the model assumes a change in average daily
dose has no impact on treatment efﬁcacy.
In addition to AC costs, a management cost per
month was applied for all ACs. Costs were obtained
from NHS reference costs.14
Routine care, monitoring costs, and costs associ-
ated with the clinical events were obtained from
published literature and expert opinion.
Stroke costs were classiﬁed according to haemor-
rhagic or non-hemorrhagic (i.e., stroke), degree of
severity (mild, moderate, severe) and type of cost
(acute or long term maintenance). Acute care con-
sisted of time spent in hospital and rehabilitation
facility. Following the acute care period, patients2488.e9
Table A2. Calculation of utility estimates used in model from EQ-5D catalogue.
ICD-9 / CCC Disease Classification Utility
Health state Code Description
Disutility for
Condition Mean SE
Atrial ﬁbrillation ICD-9 427 Cardiac Dysrhythmias -0.0384 0.7270 0.0095
Stroke (ischemic and
hemorrhagic stroke)
CCC109 Acute Cerebrovascular
Disease
-0.1009 0.5646* 0.0299
Mild Stroke CCC109 Acute Cerebrovascular
Disease
-0.05045 0.6151* 0.0299
Moderate Stroke CCC109 Acute Cerebrovascular
Disease
-0.1009 0.5646* 0.0299
Severe Stroke CCC109 Acute Cerebrovascular
Disease
-0.1535 0.5142* 0.0299
Myocardial infarction CCC100 Acute Myocardial Infarction -0.0557 0.6098* 0.0193
Systemic embolism ICD-9 444 Arterial embolism -0.039 0.6265* 0.0191
Other ICH ICD-9-442 Other aneurysm -0.0983 -0.1511† 0.0401
Other Major Bleeds ICD-9-442 Other aneurysm -0.0983 -0.1511† 0.0401
CRNM Bleeds ICD-9-599 Other urinary tract disorder -0.0053797 -0.0582† 0.0173
Other CV Hospitalization ICD-9-411;
413; 414; 428;
435; 443;
444; 453
Angina pectoris, Other
chronic ischaemic heart
disorder; heart failure;
transient cerebral
ischemia; arterial
embolism; other venous
thrombosis;
-0.0747498‡ -0.1276† 0.0259
Source: Sullivan et al. (2011)9
*The utility for semi-absorbing health states was calculated by subtracting the disutility for the condition and the disutility of
total number of chronic conditions, ncc¼2 corresponding to -0.0615 from the baseline atrial ﬁbrillation utility.
†The utility decrement for transient health states was calculated by subtracting the disutility of total number of chronic
conditions, ncc¼2 for ICD-9 codes corresponding to -0.0528.
‡Average disutility weighted by sample size.
Clinical Therapeuticsaccumulated maintenance costs until death. The acute
phase was assumed to be two weeks in the base case
as advised by experts. Costs for acute phase and long-
term maintenance for mild, moderate, severe and fatal
strokes were obtained from a published estimates of a
cost of illness model based on a large, randomised,
prospective study detailing UK costs of stroke to the
NHS.16 Costs were available for acute phase and for
ongoing care consisting of resource use items includ-
ing resource use in hospital, primary care, healthcare
contacts, and utilization of social services. The paper
did not distinguish costs between patients with hem-
orrhagic stroke or ischemic stroke. It was therefore
assumed that costs for hemorrhagic strokes were the2488.e10same as costs for ischemic strokes. Acute care costs for
SE, were assumed to be the same as those for mild
stroke.16
Costs of other major bleeds and ICH were obtained
from NHS reference costs.14 The national average cost
for hemorrhagic cerebrovascular disorders was used
to detail the cost per event of ICH. Costs of major
bleeds were broken down by the nature of the bleed
(GI bleeds, non ICH and non GI related bleeds). To
estimate the average cost of a GI related bleed to the
NHS, national average costs for GI bleeds with and
without major complications and the costs of major
procedures for GI bleeds were weighed according to
the observed activity levels (i.e. major procedures wereVolume 37 Number 11
Table A3. Anticoagulant use.
Tablet
Size
Cost Per
Tablet
Average Daily
Dose
Number of Tablets Per
Day
Average Cost Per
Day
Apixaban* 5mg £1.10 10mg 2 £2.20
Warfarin† 5mg £0.04 5mg 1 £0.04
Edoxaban
(30mg)‡
5mg £1.10 10mg 2 £2.20
Edoxaban
(60mg)‡
5mg £1.10 10mg 2 £2.20
Source:
*British National Formulary (BNF).13
†Monthly index of medical specialties (MIMS).12
‡Assuming price parity with Apixaban.
G.Y.H. Lip et al.not as common as minor GI bleeds, therefore a smaller
weight according to activity was applied to that cost
to obtain the average). The cost of GI bleeds can be
seen in the table below.
Similarly, the average cost of non-ICH and non-GI
related bleeds was obtained from a weighted average of
spinal cord conditions, non-surgical ophthalmology, gen-
eral abdominal procedures, non-inﬂammatory bone or
joint disorders, and cardiac conditions according to
observed activity levels (Table A7).14
For CRNM bleeds (Table A8), the same calculation
was used however with costs and activities related toTable A4. Management costs.‡
Anticoagulant
% of Patients Experienci
Dyspepsia Whilst
on Treatment
Apixaban* 1.67%*
Warfarin* 1.81%*
Edoxaban (30mg) 1.67%†
Edoxaban (60mg) 1.67%†
Unit cost of renal monitoring
Source:
*ARISTOTLE case study report.6
†Assumption.
‡NHS reference costs, PSSRU.14,15
§NHS reference costs.14
November 2015unspeciﬁed haematuria and intermediate nose procedures
without major complications as well as mild GI bleeds
requiring a length of stay of 1 day or less.2
Costs for the acute phase of MI were also obtained
from NHS reference costs,14 using the national aver-
age of acute or suspected MI. Additional costs of
£480 (cardiac rehabilitation and coronary revascula-
tion assessment for all patients) were applied for 12
months following MI, as described in Table A9. Long
term maintenance costs consisted of medication costs
including ACE inhibitors, beta blockers, and statins.
(Table A10).ng % of Patients Requiring
Annual Renal Monitoring
Once on Treatment
Total Monthly
Management Cost
0.00%† £ 0.04
0.00%† £ 0.04
0.00%† £ 0.04
0.00%† £ 0.04
£ 3.00§
2488.e11
Table A5. Resource use for routine care and
monitoring.
Of Visits per
Month
Frequency of routine care*
Apixaban 1.0
Aspirin 1.0
Warfarin 1.0
Edoxaban (30mg) 1.0
Edoxaban (60mg) 1.0
Frequency of INR monitoring†
cTTR o 58% 1.50
58% r cTTR o 65.7% 1.50
65.7% r cTTR o 72.2% 1.50
cTTR Z 72.2% 1.50
Source:
*Expert opinion.
†NHS reference costs.14
Clinical TherapeuticsCosts per episode of CV hospitalisation were
similarly calculated using average national costs and
activity levels from NHS reference costs (Table A11).14
The average cost was calculated using national costs
of transient ischemic attack, chest pain, deep
vein thrombosis, heart failure or shock, non-surgical
peripheral vascular disease and non interventional
acquired cardiac conditions. Currency codes and the
cost of CV hospitalization can be seen in the
following table.Table A6. Cost of GI bleeds.
HRG Code HRG Description
FZ38D Gastrointestinal bleed with length of stay
with Major CC
FZ38E Gastrointestinal bleed with length of stay
without Major CC
FZ38F Gastrointestinal bleed with length of stay
Weighted average
2488.e12MORTALITY
Rates of death based on all-cause mortality in the
AVERROES and the ARISTOTLE excluding deaths
attributable to stroke, bleeding, MI and SE (i.e., the
events modelled) to avoid double counting are used
for patients in the NVAF health state for duration of
the trial period (i.e., 1.8 years for the VKA suitable
population).
Beyond the duration of the trial period, mortality is
modeled based on background general mortality
Gompertz curves which were derived by ﬁtting a
Gompertz survival function to the 2009 UK life tables
(i.e., latest data available was 2009).17 Gompertz
curves were ﬁtted instead of using the raw data from
the life table to allow a more reﬁned estimation of the
risk of mortality for every 6- week cycle (i.e., life
tables data are yearly), and to allow for the hazard
from the ﬁtted Gompertz to be adjusted by the use of
HRs for other events. Gompertz parameters to esti-
mate background life expectancy according to age and
gender are detailed in Table A12.
In addition to background mortality, the model
allows risk adjustment factors implemented as HRs to
take into account the potential increase in mortality
rates associated with AF, strokes, haemorrhagic
strokes by severity level, MI and SE as detailed in
the manuscript. Note that since mortality due to
strokes, MI, SE, and bleedings were explicitly mod-
elled at the occurrence of the event, increased mortal-
ity for patients with AF due to these reasons were
excluded from the calculation of the HR to avoid
double counting. HR of death for patients with AF in
comparison the general population was calculatedActivity
National Average
Unit Cost
2 days or more 16,116 £2,042
2 days or more 19,304 £1,431
1 day or less 2,806 £561
£1,625
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Table A7. Cost of non-ICH and non-GI related major bleeds.
HRG Code HRG Description Activity
National Average
Unit Cost
HC28B Spinal Cord Conditions with CC 1,436 £6,047
HC28C Spinal Cord Conditions without CC 1,416 £3,315
HD24A Non-Inﬂammatory Bone or Joint Disorders with Major CC 3,906 £3,392
BZ24A Non-Surgical Ophthalmology with length of stay 2 days or more 6,809 £2,132
PA23A Cardiac Conditions with CC 2,680 £4,523
FZ12D General Abdominal - Very Major or Major Procedures 19 years
and over with Major CC
4,173 £5,905
FZ12E General Abdominal - Very Major or Major Procedures 19 years
and over with Intermediate CC
1,888 £4,114
FZ12F General Abdominal - Very Major or Major Procedures 19 years
and over without CC
2,999 £3,893
Weighted average £3,847
G.Y.H. Lip et al.based on mortality data obtained from a prospective
Swedish study.18
ANALYSIS
Univariate Sensitivity Analysis
Univariate deterministic sensitivity analysis was
performed where each parameter was varied accord-
ing to the 95% conﬁdence intervals and standard
deviations where applicable while holding all other
parameters constant. Where conﬁdence intervals and
standard deviations were unavailable, the standard
error was assumed to be 25% of the mean. Table A13
presents the range and source of variation for the
univariate sensitivity analysis for apixaban versus
edoxaban 30mg and 60mg in the VKA suitable
population. The probability distributions employed
included the beta, lognormal, uniform, gamma, and
dirichlet distributions. The distributions chosen for theTable A8. Cost of CRNM bleeds.
Currency Code Currency Descriptio
FZ38F Gastrointestinal Bleed with length of st
CZ13Y Intermediate Nose Procedures 19 years
LB38B Unspeciﬁed Haematuria without Major
Weighted average
November 2015commonly employed parameters in the model (i.e.,
probabilities, distributions [e.g., stroke severity], costs,
risks and HRs, and utilities) are detailed in Section 8.2
(Probabilistic Sensitivity Analysis).
Probabilistic Sensitivity Analysis
In order to account for variability in outcomes due
to statistical uncertainty in inputs, a PSA was per-
formed. The model was set to the probabilistic setting
and ran for 2,000 simulations to generate ICER’s by
varying event rates, costs, risks and utilities simulta-
neously. Time horizon, population characteristics and
model settings were kept constant. Key inputs were
varied from replication to replication by sampling
from probability distributions. A number of proba-
bility distributions were employed including the beta,
lognormal, uniform, gamma, and dirichlet distribu-
tions. This section describes how the distributionsn National Average Unit Cost
ay 1 day or less £562
and over without CC £946
CC £1,451
£1,183
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Table A9. MI acute costs.
HRG Code
HRG
Description Activity
National
Average
Unit Cost
EB10Z Actual or
Suspected MI
56,823 £1967
Component Unit Cost Source % Patients Expected Cost
Cardiac rehabilitation £480 Total cost per patient referred 56% £269
Coronary
revasculation
assessment
£170 320 Cardiology from NHS Trusts
and PCTs combined Consultant
Led: First Attendance Non-
Admitted Face to Face
78% £133
Clinical Therapeuticswere chosen for the commonly employed parameters
in the model (i.e., probabilities, distributions [e.g.,
stroke severity], costs, risks and HRs, and utilities).
The distributions used are detailed in Table A14.
Probabilities
The probabilities used in the model were based on
the proportion of the observed outcomes of interest
(for example, proportion of hemorrhagic strokes
among ICH, with the patients with aemorrhagicTable A10. Long-term costs of pharmaco-management
Therapy Strength
Pack
Size
Pack
Price
Price pe
Pill
Beta-blocker
(Atenolol)
25mg tablet 28 £0.87 £0.03
50mg tablet 28 £0.89 £0.03
100mg tablet 28 £0.94 £0.03
ACE inhibitor
(Ramipril)
1.25mg
capsule
28 £1.15 £0.04
2.5mg
capsule
28 £1.23 £0.04
5mg capsule 28 £1.32 £0.05
Statin
(simvastatin)
10mg tablet 28 £0.90 £0.03
20mg tablet 28 £0.97 £0.03
40mg tablet 28 £1.24 £0.04
Total
2488.e14strokes considered as success and patients without
hemorrhagic stroke considered as failure). It was
therefore possible to assume a binomial distribution
form with the number of successes denoting the
probability used in the model. Rather than using a
frequentist approach to generating conﬁdence inter-
vals through a normal distribution which could lead
to observations below 0 or above 1,19 a beta distri-
bution was chosen for probabilities as it is a conjugate
of the binomial and is bounded by 0 and 1. Theof MI.
r Daily
Dose
Pills
per
Day
Mont-
hly
Cost
Share of
Prescript-
ions
Weighted
Monthly
Cost
100mg 4 £3.78 31.97% £2.40
2 £1.94 53.95%
1 £1.02 14.08%
10mg 8 £10.00 24.68% £4.67
4 £5.35 1.43%
2 £2.87 73.89%
40mg 4 £3.91 0.37% £1.50
2 £2.11 18.09%
1 £1.35 81.54%
£8.56
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Table A11. Cost of other CV hospitalization.
Currency Code Currency Description Activity
National Average
Unit Cost
AA29A Transient Ischemic Attack with CC 10,722 £1,343
AA29B Transient Ischemic Attack without CC 362 £1,059
PA22Z Chest Pain 399 £1,175
QZ20Z Deep Vein Thrombosis 8,715 £1,718
EB03H Heart Failure or Shock with CC 50,431 £2,716
EB03I Heart Failure or Shock without CC 23,804 £1,884
QZ17A Non-Surgical Peripheral Vascular Disease with Major CC 1,545 £3,953
QZ17B Non-Surgical Peripheral Vascular Disease with Intermediate CC 10,946 £2,528
QZ17C Non-Surgical Peripheral Vascular Disease without CC 2,473 £1,848
EB01Z Non interventional acquired cardiac conditions 102,395 £1,217
Weighted average £1,770
G.Y.H. Lip et al.parameterisation of the beta used consists of denoting
the shape parameter (i.e., alpha) as the number of
successes (hemorrhagic stroke observations in this
example) and the scale parameter (i.e., beta) as the
number of failures (non-haemorrhagic stroke obser-
vations). The source of variation where probabilities
were involved was therefore patient numbers obtained
from the trials or published estimates.
Distributions
Some probabilities used in the model however
cannot be described by positive and negative occur-
rences, but were however used to describe the distri-
bution of patients amongst a number of different
occurrences (e.g., in the case of assigning stroke
severity where patients are segregated by mild, mod-
erate, severe and fatal). The distribution of severity
was important to include in the PSA as it varied byTable A12. Background mortality — Gompertz
survival functions.
Lambda Gamma
Males o75 years old −9.2268 0.0745
Males Z75 years old −9.3652 0.0835
Females o75 years old −9.6037 0.0717
Females Z75 years old −10.9334 0.0986
November 2015comparators. In addition, as noted in the methods
section, alternative costs, HRs of deaths, and utilities
were assigned according to the severity level so it was
imperative to capture the uncertainty around them.
The Dirichlet distribution, a multivariate generalisa-
tion of the beta distribution was used for these
parameters as it allowed for a number of categories
to be ﬁt in a probabilistic manner. We followed a
normalised sum of independent gamma or normal
variable as described in Briggs et al. (2003).20 This
involved generating the number of patients in each of
the mild, moderate, severe and fatal health states in
each simulation and calculating the proportion in each
health state from their total sum. A gamma distribu-
tion was used to generate the patient numbers using
the number of patients observed in each category as
the shape parameter (i.e., alpha) and one as the scale
parameter (i.e., beta). Alternatively a normal distribu-
tion was used using the number of patients observed
in each category as the mean and the square root of
the number of patients as the standard deviation. The
gamma was chosen when patient numbers was small
to avoid the normal generating negative patient
numbers.Costs
With resource use and unit costs it was imperative
that the distribution chosen had a lower bound of 0 to
avoid the generation of any “negative” costs. The
gamma distribution is therefore often used due to its2488.e15
Table A13. Range of variation for univariate sensitivity analysis apixaban versus edoxaban 30mg/ 60mg VKA
suitable population.
Description
Base Case
Value
Lower
Value
Upper
Value
Gender (% Male) 0.65 0.63 0.66
Mean age for males 70.00 63.00 77.00
Mean age for females 70.00 63.00 77.00
Risk of ischemic and unspeciﬁed stroke for apixaban (Rate/100 PYs) 0.98 0.56 1.52
Risk of ischemic and unspeciﬁed stroke for warfarin (Rate/100 PYs) 1.08 0.87 1.33
Risk adjustment factor for stroke per decade 1.46 0.80 2.16
Case fatality rate of stroke (excluding hemorrhagic strokes) for apixaban 0.18 0.11 0.26
Case fatality rate of stroke (excluding hemorrhagic strokes) for
Edoxaban (30mg)/(60mg)
0.20/0.29 0.15/0.22 0.25/0.36
Risk of intracranial hemorrhage (ICH) for apixaban (Rate/100 PYs) 0.33 0.19 0.51
Risk of intracranial hemorrhage (ICH) for warfarin (Rate/100 PYs) 0.80 0.35 1.87
Risk adjustment factor for ICH per decade 1.97 1.79 2.16
Proportion of hemorrhagic strokes among ICHs for apixaban 0.77 0.65 0.87
Proportion of hemorrhagic strokes among ICHs for Edoxaban
(30mg)/(60mg)
0.69/0.75 0.56/0.63 0.80/0.85
Case fatality rate of hemorrhagic stroke for apixaban 0.35 0.20 0.52
Case fatality rate of hemorrhagic stroke for Edoxaban (30mg)/(60mg) 0.20/0.29 0.15/0.22 0.25/0.36
Risk of other major bleeds for apixaban (Rate/100PYs) 1.79 1.02 2.77
Risk of other major bleeds for warfarin (Rate/100PYs) 2.27 1.30 3.51
Risk adjustment factor for other major bleeds per decade 1.97 1.79 2.16
Proportion of gastrointestinal (GI) bleeds among other major bleeds for
apixaban
0.38 0.32 0.44
Proportion of GI bleeds among other major bleeds for Edoxaban
(30mg)/(60mg)
0.61/0.65 0.56/0.60 0.66/0.70
Risk of clinically relevant non major bleeds (CRNMB) for apixaban
(Rate/100PYs)
2.08 1.19 3.22
Risk of CRNMB for warfarin (Rate/100PYs) 3.00 2.59 3.45
Risk adjustment factor for CRNMB per decade 1.97 1.79 2.16
Case fatality rate of ICH for apixaban 0.13 0.06 0.22
Case fatality rate of ICH for Edoxaban (30mg)/(60mg) 0.13/0.13 0.06/0.06 0.22/
0.0.22
Case fatality rate of other major bleeds for apixaban 0.02 0.01 0.03
Case fatality rate of other major bleeds for Edoxaban (30mg)/(60mg) 0.02/0.02 0.01/0.01 0.03/0.03
% switch treatment post ICH for apixaban 0.56 0.43 0.69
% switch treatment post ICH for Edoxaban (30mg)/(60mg) 0.56/0.56 0.43/0.43 0.69/0.69
% switch treatment post GI for apixaban 0.25 0.01 0.69
% switch treatment post GI for Edoxaban (30mg)/(60mg) 0.25/0.25 0.01/0.01 0.69/0.69
Risk of MI for apixaban (Rate/100PYs) 0.53 0.30 0.82
Risk of MI for warfarin (Rate/100PYs) 0.61 0.45 0.80
Risk of cardiovascular (CV) hospitalization for apixaban (Rate/100 PYs) 10.46 5.98 16.17
Risk of cardiovascular (CV) hospitalization for warfarin (Rate/100 PYs) 10.46 5.98 16.17
Risk of other treatment discontinuations for apixaban (Rate/100 PYs) 13.18 7.53 20.38
(continued)
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Table A13. (continued).
Description
Base Case
Value
Lower
Value
Upper
Value
Risk of other treatment discontinuations for warfarin (Rate/100 PYs) 14.41 8.23 22.27
Risk of ischaemic and unspeciﬁed strokes for aspirin 2nd line
(Rate/100 PYs)
3.45 1.97 5.34
Risk of ICH for aspirin 2nd line (Rate/100 PYs) 0.32 0.18 0.50
Risk of other major bleeds for aspirin 2nd line (Rate/100 PYs) 0.89 0.51 1.37
Risk of CRNMB for aspirin 2nd line (Rate/100 PYs) 2.94 1.68 4.54
Risk of MI for aspirin 2nd line (Rate/100 PYs) 1.11 0.63 1.72
Risk of CV hospitalization for aspirin 2nd line (Rate/100 PYs) 13.57 7.76 20.98
Case fatality rate of stroke (excluding hemorrhagic strokes) for
aspirin 2nd line
0.11 – –
Utility AF 0.73 0.71 0.75
Utility stroke mild 0.62 0.56 0.67
Utility stroke moderate 0.56 0.51 0.62
Utility stroke severe 0.51 0.46 0.57
Utility hemorrhagic stroke mild 0.62 0.56 0.67
Utility hemorrhagic stroke moderate 0.56 0.51 0.62
Utility hemorrhagic stroke severe 0.51 0.46 0.57
Utility decrement: ICH 0.15 0.08 0.24
Utility decrement: other major bleed 0.15 0.08 0.24
Utility decrement: CRNMB 0.06 0.03 0.10
Utility decrement: MI 0.61 0.57 0.65
Utility decrement: Other CV hospitalisation 0.13 0.08 0.18
Utility decrement: aspirin 2nd line 0.00 – 0.04
Utility decrement: Warfarin 0.01 – 0.08
Hazard Ratio for long-term mortality post ischemic & unspeciﬁed stroke
mild
3.18 1.42 4.94
Hazard Ratio for long-term mortality post ischemic & unspeciﬁed stroke
moderate
5.84 4.08 7.60
Hazard Ratio for long-term mortality post ischemic & unspeciﬁed stroke
severe
15.75 13.99 17.51
Hazard Ratio for long-term mortality post hemorrhagic stroke mild 3.18 1.82 4.92
Hazard Ratio for long-term mortality post hemorrhagic stroke moderate 5.84 3.34 9.03
Hazard Ratio for long-term mortality post haemorrhagic stroke severe 15.75 9.00 24.35
Daily cost of apixaban 1.10 0.88 1.32
Daily cost of edoxaban (30mg)/(60mg) 1.10/ 1.10 0.88/0.88 1.32/ 1.32
Monitoring visit cost 14.27 11.94 17.05
Routine care cost – – 113.00
Acute care stroke costs mild 3,639.20 0.00 27,659.60
Long-term follow-up stroke costs mild 190.38 0.01 1,143.69
Acute care stroke costs Moderate 18,985.67 303.46 74,272.57
Long-term follow-up stroke costs Moderate 371.39 0.00 2,370.09
Acute care stroke costs Severe 25,931.29 3,667.32 69,504.41
Long-term follow-up stroke costs Severe 563.91 0.00 4,448.40
(continued)
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Table A13. (continued).
Description
Base Case
Value
Lower
Value
Upper
Value
Acute care hemorrhagic stroke costs mild 10,596.58 3,350.63 21,939.02
Long-term follow-up hemorrhagic stroke costs mild 190.38 0.01 1,143.69
Acute care hemorrhagic stroke costs Moderate 27,223.89 10,922.42 50,840.05
Long-term follow-up hemorrhagic stroke costs Moderate 371.39 0.00 2,370.09
Acute care hemorrhagic stroke costs Severe 46,050.13 26,321.63 71,205.64
Long-term follow-up hemorrhagic stroke costs Severe 563.91 0.00 4,448.40
Other ICH cost 3,231.13 2,415.24 3,796.05
Cost of GI 1,624.88 1,273.70 1,853.55
Non ICH and non GI Major bleed cost 3,846.67 2,495.78 4,560.37
CRNM bleeds cost 1,183.13 864.36 1,371.45
MI Acute care cost 2,367.92 1,721.00 2,826.00
MI long-term follow-up cost 8.56 4.89 13.24
CV hospitalization cost 1,770.42 1,275.29 1,998.88
Stroke Hazard ratio for Edoxaban (30mg)/(60mg) 1.48/ 1.04 1.12/0.78 1.96/1.39
ICH Hazard ratio for Edoxaban (30mg)/(60mg) 0.74/ 1.11 0.46/0.71 1.20/1.73
MI Hazard ratio for Edoxaban (30mg)/(60mg) 1.37/ 1.07 0.95/0.74 1.96/1.55
Cardiovascular hospitalization Hazard ratio for Edoxaban (30mg)/(60mg) 1.00/ 1.00 0.90/0.90 1.10/1.10
Major Bleed Hazard ratio for Edoxaban (30mg)/(60mg) 0.66/ 1.13 0.53/0.91 0.83/1.39
CRNM Hazard ratio for Edoxaban (30mg)/(60mg) 0.95/ 1.15 0.80/1.06 1.13/1.48
Treatment discontinuation Hazard ratio for Edoxaban (30mg)/(60mg) 1.04/ 1.10 0.96/1.01 1.13/1.19
Risk of recurrent IS 2.72 3.41 4.91
Risk of recurrent HS 2.72 2.02 4.46
Risk of SE for apixaban (Rate/100PYs) 0.09 0.05 0.14
Risk of SE for warfarin (Rate/100PYs) 0.10 0.06 0.15
Utility: SE 0.63 0.59 0.66
Case fatality rate of SE for apixaban 0.09 0.02 0.21
Case fatality rate of SE for Edoxaban (30mg)/(60mg) 0.09/0.09 0.02/0.02 0.21/0.21
Hazard Ratio for long-term mortality post systemic embolism 1.34 1.20 3.18
Hazard Ratio for long-term mortality post MI females 4.16 3.44 5.03
Hazard Ratio for long-term mortality post MI males 2.56 2.27 2.88
Case fatality rate of MI females 0.16 0.09 0.24
Case fatality rate of MI females 0.11 0.06 0.17
Acute care SE costs 4,221.30 0.01 27,909.69
Long-term follow-up SE cost 190.38 0.01 1,143.69
Management cost of apixaban 0.04 0.02 0.06
Management of Edoxaban (30mg)/(60mg) 0.04/0.04 0.02/0.02 0.06/0.06
SE Hazard ratio for Edoxaban (30mg)/(60mg) 1.39/0.74 0.57/0.29 3.36/ 1.92
Rate of death apixaban trial period 3.08 2.50 3.72
Rate of death comparator trial period 3.34 2.71 4.04
HR mortality trial period comparator 1.00 0.90 1.10
HR mortality AF 1.34 1.20 1.53
Disutility associated with age – – 0.00029
Clinical Therapeutics
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Table A14. Distributions used for probabilistic sensitivity analysis.
Description Detail Mean Distribution SE Shape Scale Source of Variation
Stroke risk for apixaban VKA
suitable population
CHADS ¼ 0-1 0.52 Gamma 0.09 31.38 0.02 Standard errors from source
CHADS ¼ 2 0.95 Gamma 0.13 56.85 0.02
CHADS Z3 1.53 Gamma 0.18 74.27 0.02
Stroke risk for warfarin VKA
suitable population
CHADS ¼ 0-1 0.46 Gamma 0.09 26.48 0.02 Standard errors from source
CHADS ¼ 2/ 0.93 Gamma 0.12 56.73 0.02
CHADS Z3 1.94 Gamma 0.20 91.71 0.02
Stroke HR VKA suitable Edoxaban (30mg) 1.48 Lognormal 0.29 Iterated SE to match 95%
Conﬁdence intervals
provided by ITC
Edoxaban (60mg) 1.04 Lognormal 0.29
Risk adjustment per decade
for stroke
VKA Suitable 1.46 Gamma 0.37 16.00 0.09 Assumed 25% SE of the mean
Risk of stroke recurrence VKA Suitable 0.041 Gamma 0.004 118.15 0.00035 SEs from source
Risk of haemorrhagic stroke
recurrence
VKA Suitable 2.720 Gamma 0.594 20.94 0.13 SEs from source
% Mild strokes - VKA
suitable population
Apixaban 0.53 Dirichlet 57 Patient numbers from trials
Edoxaban (30mg) 0.50 Dirichlet 89.00
Edoxaban (60mg) 0.47 Dirichlet 90.00
% moderate strokes - VKA
suitable population
Apixaban 0.21 Dirichlet 23.00 Patient numbers from trials
Edoxaban (30mg) 0.22 Dirichlet 33.00
Edoxaban (60mg) 0.18 Dirichlet 34.00
% severe strokes - VKA
suitable population
Apixaban 0.08 Dirichlet 9.00 Patient numbers from trials
Edoxaban (30mg) 0.08 Dirichlet 12.00
Edoxaban (60mg) 0.06 Dirichlet 13.00
% fatal strokes - VKA
suitable population
Apixaban 0.18 Dirichlet 19.00 Patient numbers from trials
Edoxaban (30mg) 0.20 Dirichlet 48.00
Edoxaban (60mg) 0.29 Dirichlet 49.00
ICH risk apixaban - VKA
suitable population
Apixaban 0.33 Gamma 0.08 16.00 0.02 Assumed 25% SE of the mean
ICH risk warfarin- VKA
suitable population
Warfarin 0.80 Gamma 0.14 34.60 0.02
(continued)
G
.Y
.H
.
Lip
et
al.
N
o
vem
b
er
2
0
1
5
2
4
8
8
.e1
9
Table A14. (continued).
Description Detail Mean Distribution SE Shape Scale Source of Variation
ICH HR VKA suitable Edoxaban (30mg) 0.74 Lognormal 0.49 Iterated SE to match 95%
Conﬁdence intervals
provided by ITC
Edoxaban (60mg) 1.11 Lognormal 0.45
% of hemorrhagic strokes
among ICH - VKA suitable
Apixaban 0.77 Beta 52.00 40.04 11.96 Patient numbers from trials
Warfarin 0.64 Beta 122.00 78.08 43.92
Edoxaban (30mg) 0.69 Beta 56.00
Edoxaban (60mg) 0.75 Beta 57.00
% Mild hemorrhagic strokes -
VKA suitable population
Apixaban 0.23 Dirichlet 7.00 Patient numbers from trials
Warfarin 0.20 Dirichlet 13.00
Edoxaban (30mg) 0.50 Dirichlet 89.00
Edoxaban (60mg) 0.47 Dirichlet 90.00
% moderate hemorrhagic
strokes - VKA suitable
population
Apixaban 0.32 Dirichlet 10.00 Patient numbers from trials
Warfarin 0.15 Dirichlet 10.00
Edoxaban (30mg) 0.22 Dirichlet 33.00
Edoxaban (60mg) 0.18 Dirichlet 34.00
% severe hemorrhagic strokes
- VKA suitable population
Apixaban 0.10 Dirichlet 3.00 Patient numbers from trials
Warfarin 0.12 Dirichlet 8.00
Edoxaban (30mg) 0.08 Dirichlet 12.00
Edoxaban (60mg) 0.06 Dirichlet 13.00
% fatal hemorrhagic strokes -
VKA suitable population
Apixaban 0.35 Dirichlet 11.00 Patient numbers from trials
Warfarin 0.53 Dirichlet 34.00
Edoxaban (30mg) 0.20 Dirichlet 48.00
Edoxaban (60mg) 0.29 Dirichlet 49.00
Major bleed risk apixaban
VKA suitable
Apixaban 1.79 Gamma 0.45 16.00 0.11 Assumed 25% SE of the mean
Major bleed risk warfarin
VKA suitable
Warfarin 2.27 Gamma 0.57 16.00 0.14
HR Major bleed VKA suitable Warfarin 1.27 Lognormal Iterated SE to match 95%
Conﬁdence intervals
provided by ITC
Edoxaban (30mg) 0.66 Lognormal 0.23
Edoxaban (60mg) 1.13 Lognormal 0.22
% Patients with GI bleeds
VKA suitable
Apixaban 0.38 Beta 274.00 104.12 169.88 Patient numbers from trials
Warfarin 0.35 Beta 340.00 119.00 221.00
(continued)
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Table A14. (continued).
Description Detail Mean Distribution SE Shape Scale Source of Variation
Edoxaban (30mg) 0.61 Beta 396.00 241.56 154.44
Edoxaban (60mg) 0.65 Beta 397.00 258.05 138.95
CRNM risk apixaban VKA
suitable
Apixaban 2.08 Gamma 0.52 16.00 0.13 Assumed 25% SE of the mean
CRNM risk warfarin VKA
suitable
Warfarin 3.00 Gamma 0.75 16.00 0.19
HR CRNM VKA suitable Warfarin 1.43 Lognormal 0.07 Iterated SE to match 95%
Conﬁdence intervals
provided by ITC
Edoxaban (30mg) 0.95 Lognormal 1.09
Edoxaban (60mg) 1.25 Lognormal 2.09
ICH risk per decade
adjustment
VKA Suitable 1.97 Gamma 0.49 16.00 0.12 Assumed 25% SE of the mean
Major bleed risk per decade
adjustment
VKA Suitable 1.97 Gamma 0.49 16.00 0.12 Assumed 25% SE of the mean
CRNM risk per decade
adjustment
VKA Suitable 1.97 Gamma 0.49 16.00 0.12 Assumed 25% SE of the mean
% Case fatality rate for ICH
in the VKA suitable
population
Apixaban 0.13 Beta 62.00 8.06 53.94 Patient numbers from trials
Warfarin 0.13 Beta 62.00 8.06 53.94
Edoxaban (30mg) 0.13 Beta 63.00 8.19 54.81
Edoxaban (60mg) 0.13 Beta 64.00 8.32 55.68
% Case fatality rate for major
bleeds in the VKA suitable
population
Apixaban 0.02 Beta 750.00 15.00 735.00 Patient numbers from trials
Warfarin 0.02 Beta 750.00 15.00 735.00
Edoxaban (30mg) 0.02 Beta 751.00 15.02 735.98
Edoxaban (60mg) 0.02 Beta 752.00 15.04 736.96
% Patients that Stop AC for 6
Weeks Post Other ICH
VKA suitable
Apixaban 0.44 Beta 52.27 23.00 29.27 Patient numbers
Warfarin 0.44 Beta 52.27 23.00 29.27
Edoxaban (30mg) 0.44 Beta 52.27 23.00 29.27
Edoxaban (60mg) 0.44 Beta 52.27 23.00 29.27
% Patients that don’t switch
AC Post GI VKA suitable
Apixaban 0.75 Beta 0.19 3.25 1.08 Assumed 25% SE of the mean
Warfarin 0.75 Beta 0.19 3.25 1.08
Edoxaban (30mg) 0.75 Beta 0.19 3.25 1.08
Edoxaban (60mg) 0.75 Beta 0.19 3.25 1.08
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Table A14. (continued).
Description Detail Mean Distribution SE Shape Scale Source of Variation
% Patients that don’t switch
AC Post non-GI VKA
suitable
Apixaban 0.75 Beta 0.19 3.25 1.08 Assumed 25% SE of the mean
Warfarin 0.75 Beta 0.19 3.25 1.08
Edoxaban (30mg) 0.75 Beta 0.19 3.25 1.08
Edoxaban (60mg) 0.75 Beta 0.19 3.25 1.08
MI risk apixaban VKA
suitable
Apixaban 0.53 Gamma 0.13 16.00 0.03 Assumed 25% SE of the mean
MI risk warfarin VKA suitable Warfarin 0.61 Gamma 0.15 16.00 0.04
HR MI VKA suitable Warfarin 1.14 Lognormal 0.13 Iterated SE to match 95%
Conﬁdence intervals
provided by ITC
MI CFR Males VKA suitable 0.108 Beta 0.03 14.16 116.98 Assumed 25% SE of the mean
MI CFR Females VKA
suitable
0.156 Beta 0.04 13.35 72.22 Assumed 25% SE of the mean
MI risk per decade
adjustment
VKA Suitable 1.3 Gamma 0.3 16.0 0.1 Assumed 25% SE of the mean
SE risk apixaban VKA
suitable
Apixaban 0.090 Gamma 0.023 16.00 0.00563
SE risk warfarin VKA suitable Warfarin 0.100 Gamma 0.023 16.00 0.00625
SE CFR VKA suitable All comparators 0.094 Beta 3.00 29.00 Based on patient numbers
CV hospitalization risk
apixaban VKA suitable
Apixaban 10.46 Gamma 2.62 16.00 0.65
CV hospitalization risk
warfarin VKA suitable
Warfarin 10.46 Gamma 2.62 16.00 0.65
Other treatment
discontinuation risk
apixaban VKA suitable
Apixaban 13.17 Gamma 3.3 16.0 0.8 Assumed 25% SE of the mean
Other treatment
discontinuation risk
warfarin VKA suitable
Warfarin 14.41 Gamma 3.6 16.0 0.9
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Table A14. (continued).
Description Detail Mean Distribution SE Shape Scale Source of Variation
HR Other treatment
discontinuation VKA
suitable
Edoxaban (30mg) 1.04 Lognormal 0.08 Iterated SE to match 95%
Conﬁdence intervals
provided by ITC
Edoxaban (60mg) 1.10 Lognormal 0.08
Relative rate of death for AF 1.34 Uniform 1.20 1.53 Assumed upper and lower
bound based on GPRD
studies18,21
Other death rate apixaban VKA suitable 3.08 Gamma 0.31 99 0.03 Calculated based on number
of events
HR of death for stroke Mild (mRS 0-2) 3.18 Gamma 0.80 16 0.20 Assumed 25% SE of the mean
Moderate (mRS 3-4) 5.84 Gamma 1.46 16 0.37
Severe (mRS 5) 15.75 Gamma 3.94 16 0.98
HR of death for hemorrhagic
stroke
Mild (mRS 0-2) 3.18 Gamma 0.80 16 0.20 Assumed 25% SE of the mean
Moderate (mRS 3-4) 5.84 Gamma 1.46 16 0.37
Severe (mRS 5) 15.75 Gamma 3.94 16 0.98
MI HR Males 2.56 Gamma 0.64 16 0.16 Assumed 25% SE of the mean
MI HR Females 4.16 Gamma 1.04 16 0.26 Assumed 25% SE of the mean
SE HR 1.34 Gamma 0.34 16 0.08 Assumed 25% SE of the mean
Event costs Monitoring Visit £ 14.27 Lognormal 0.09 2.66 Iterated SE to obtain similar
conﬁdence intervals as
reported in source
Routine Care Visit £ 0.00 0.00
Mild Ischemic Stroke
Acute Care (per
episode)
£ 3,639.20 Gamma 8195.42 0.20 18455.95 Assumed 25% SE of the mean
Mild Ischemic Stroke
Maintenance Care (per
month)
£ 190.38 Lognormal 327.70 0.34 564.07 Iterated SE to obtain similar
conﬁdence intervals as
reported in source
Moderate Ischemic Stroke
Acute Care (per episode)
£ 18,985.67 Gamma 20315.73 0.87 21738.97 Assumed 25% SE of the mean
Moderate Ischemic Stroke
Maintenance Care (per
month)
£ 371.39 Lognormal 683.75 0.30 1258.82 Iterated SE to obtain similar
conﬁdence intervals as
reported in source
(continued)
G
.Y
.H
.
Lip
et
al.
N
o
vem
b
er
2
0
1
5
2
4
8
8
.e2
3
Table A14. (continued).
Description Detail Mean Distribution SE Shape Scale Source of Variation
Severe Ischemic Stroke
Acute Care (per episode)
£ 25,931.29 Gamma 17411.00 2.22 11690.24 Assumed 25% SE of the mean
Severe Ischemic Stroke
Maintenance Care (per
month)
£ 563.91 Lognormal 1328.45 0.18 3129.54 Iterated SE to obtain similar
conﬁdence intervals as
reported in source
Fatal stroke cost per
episode
£ 3,273.24 Gamma 3004.67 1.19 2758.14 Assumed 25% SE of the mean
Mild Hemorrhagic Stroke
Acute Care (per episode)
£ 10,596.58 Gamma 4825.87 4.82 2197.79 Assumed 25% SE of the mean
Mild Hemorrhagic Stroke
Maintenance Care (per
month)
£ 190.38 Lognormal 327.70 0.34 564.07 Iterated SE to obtain similar
conﬁdence intervals as
reported in source
Moderate Hemorrhagic
Stroke Acute Care (per
episode)
£ 27,223.89 Gamma 10309.00 6.97 3903.76 Assumed 25% SE of the mean
Moderate Hemorrhagic
Stroke Maintenance
Care (per month)
£ 371.39 Lognormal 683.75 0.30 1258.82 Iterated SE to obtain similar
conﬁdence intervals as
reported in source
Severe Hemorrhagic
Stroke Acute Care (per
episode)
£ 46,050.13 Gamma 11512.53 16.00 2878.13 Assumed 25% SE of the mean
Severe Hemorrhagic
Stroke Maintenance
Care (per month)
£ 563.91 Lognormal 1328.45 0.18 3129.54 Iterated SE to obtain similar
conﬁdence intervals as
reported in source
Fatal stroke cost per
episode
£ 1,703.50 Gamma 2018.09 0.71 2390.78 Assumed 25% SE of the mean
SE Acute Care (per
episode)
£ 4,221.30 Lognormal 8087.34 0.27 15494.06 Assumed 25% SE of the mean
SE Maintenance Care (per
month)
£ 190.38 Lognormal 327.70 0.34 564.07 Assumed 25% SE of the mean
Other ICH (excluding
hemorrhagic stroke)
£ 3,231.13 Lognormal 704.50 21.04 153.60
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Table A14. (continued).
Description Detail Mean Distribution SE Shape Scale Source of Variation
Other Major Bleed GI
(excluding ICH)
£ 1,624.88 Lognormal 295.84 30.17 53.86
Other Major Bleed Non-GI
(excluding ICH)
£ 3,846.67 Lognormal 1053.36 13.34 288.45
CRNM Bleed £ 1,183.13 Lognormal 258.72 20.91 56.58
MI Acute Care (per
episode)
£ 2,367.92 Lognormal 563.78 17.64 134.23
MI Maintenance Care (per
month)
£ 8.56 Gamma 2.14 16.00 0.54
Other CV Hospitalization £ 1,770.42 Lognormal 369.18 23.00 76.98
Utilities AF Baseline 0.73 Beta 0.01 1598.04 600.09 SE provided in source
Mild Ischemic Stroke 0.62 Beta 0.03 162.27 101.55
Moderate Ischemic Stroke 0.56 Beta 0.03 154.69 119.28
Severe Ischemic Stroke 0.51 Beta 0.03 143.15 135.26
Mild Hemorrhagic Stroke 0.62 Beta 0.03 162.27 101.55
Moderate Hemorrhagic
Stroke
0.56 Beta 0.03 154.69 119.28
Severe Hemorrhagic
Stroke
0.51 Beta 0.03 143.15 135.26
Utility decrements Other ICH 0.15 Beta 0.04 11.88 66.75 SE provided in source
Other Major Bleed 0.15 Beta 0.04 11.88 66.75
CRNM Bleed 0.06 Beta 0.02 10.56 170.95
MI 0.12 Beta 0.02 32.53 245.02
Other CV Hospitalization 0.13 Beta 0.03 21.01 143.68
Warfarin 0.01 Beta 0.00 15.80 1,300.54 Assumed 25% SE of the mean
Utility decrement associated
with age
0.0000 Uniform 0.0000 0.00029 Assumed upper bound from
Sullivan et al. (2011)9
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Clinical Therapeuticsconstrained intervals.19 Standard deviations were used
along with the mean to obtain the shape and scale
parameters of the gamma distribution. Alternatively
the lognormal distribution can be used. Both distri-
butions can be highly skewed to reﬂect the natural
skew in costs. Where standard deviations were not
available, the standard deviations were derived from
the 95% conﬁdence intervals. Alternatively a 25%
standard deviation of the mean was assumed.Hazard Ratios
For HRs, due to the nature of calculation of the
conﬁdence intervals of these parameters in the clinical
trials in which the central limit theorem was em-
ployed, the natural logarithm of the parameters can
often be normally distributed.19 A log-normal distri-
bution was therefore used where it could replicate the
conﬁdence intervals generated from the trials. As
conﬁdence intervals were available for some of these
parameters the standard deviations were derived to
obtain the same conﬁdence intervals from the distri-
butions as those reported. Similarly where conﬁdence
intervals were unavailable a 25% standard deviation
of the mean was assumed.
For HRs of death, the gamma distribution was used
assuming a 25% standard deviation of the mean.Utilities
For utilities, a beta distribution was used due to the
bounds of the distribution (i.e., 0 to 1).19 Standard
deviations were taken from the published literature
and in some cases the published papers provided the
shape and scale parameters of the distribution.
Other model parameters such as time horizon,
population characteristics, anticoagulant costs, dura-
tion of utility decrements, and resource use were not
varied. The tables below present the inputs, variables
and assumptions for the PSA. The PSA for base case
were run for 2,000 replications where repeated sam-
ples were drawn from probability distributions to
determine an empirical distribution for costs, QALYs
to construct a range of cost-effectiveness ratios. Cost-
effectiveness acceptability curves (CEACs) were then
generated.
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